**Name of journal: *World Journal of Clinical Cases***

**ESPS Manuscript NO: 15578**

**Columns: REVIEW**

**From variome to phenome: Pathogenesis, diagnosis and management of ectopic mineralization disorders**

De Vilder EYG *et al*. Variome to phenome: Ectopic mineralization disorders

Eva Yvette Gerona De Vilder, Olivier Madeleine Vanakker

**Eva Yvette Gerona De Vilder, Olivier Madeleine Vanakker,** Center for Medical Genetics, Ghent University Hospital, B-9000 Ghent, East Flanders, Belgium

**Eva Yvette Gerona De Vilder,** Department of Ophthalmology, Ghent University Hospital, B-9000 Ghent, East Flanders, Belgium

**Eva Yvette Gerona De Vilder,** PhD Fellow of the Research Foundation - Flanders.

**Author contributions:** De Vilder EYG wrote the paper; Vanakker OM edited the paper.

**Supported by** the Research Foundation Flanders (FWO) (FWO14/ASP/084), Vanakker OM is a senior clinical investigator at the Fund for Scientific Research-Flanders. Contract grant sponsor: FWO grant number G.0241.11N and Methusalem grant number 08/01M01108.

**Conflict-of-interest:** The authors declare no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Vanakker Olivier, MD, PhD,** Center for Medical Genetics, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, East Flanders, Belgium. [olivier.vanakker@ugent.be](mailto:olivier.vanakker@ugent.be)

**Telephone:** +32-9-3323603

**Fax:** +32-9-3324970

**Received:** November 29, 2014

**Peer-review started:** November 29, 2014

**First decision:** February 7, 2015

**Revised:** February 27, 2015

**Accepted:** May 16, 2015

**Article in press:**

**Published online:**

**Abstract**

Ectopic mineralization - inappropriate biomineralization in soft tissues - is a frequent finding in physiological aging processes and several common disorders, which can be associated with significant morbidity and mortality. Further, pathologic mineralization is seen in several rare genetic disorders, which often present life-threatening phenotypes. These disorders are classified based on the mechanisms through which the mineralization occurs: metastatic or dystrophic calcification or ectopic ossification. Underlying mechanisms have been extensively studied, which resulted in several hypotheses regarding the etiology of mineralization in the extracellular matrix of soft tissue. These hypotheses include intracellular and extracellular mechanisms, such as the formation of matrix vesicles, aberrant osteogenic and chondrogenic signaling, apoptosis and oxidative stress. Though coherence between the different findings is not always clear, current insights have led to improvement of the diagnosis and management of ectopic mineralization patients, thus translating pathogenetic knowledge (variome) to the phenotype (phenome). In this review, we will focus on the clinical presentation, pathogenesis and management of primary genetic soft tissue mineralization disorders. As examples of dystrophic calcification disorders Pseudoxanthoma elasticum, Generalized arterial calcification of infancy, Keutel syndrome, Idiopathic basal ganglia calcification and Arterial calcification due to CD73 (NT5E) deficiency will be discussed. Hyperphosphatemic familial tumoral calcinosis will be reviewed as an example of mineralization disorders caused by metastatic calcification.

**Key words**: Ectopic mineralization; Pseudoxanthoma elasticum; Pseudoxanthoma elasticum-like syndrome; Generalized arterial calcification of infancy; Keutel syndrome; Idiopathic basal ganglia calcification; Arterial calcification due to CD73 deficiency; Hyperphosphatemic familial tumoral calcinosis; Etiology; Phenotype

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Ectopic mineralization disorders represent a broad range of phenotypically heterogenous diseases, often leading to significant morbidity and mortality. Involving a complex interplay between different pro-osteogenic mediators and inhibitors of calcification, the mechanisms of ectopic mineralization are progressively being unveiled. Though current knowledge is beyond any doubt the tip of the proverbial iceberg, insights already have significant implications in the diagnosis and daily management of these patients. As such, ectopic mineralization diseases are a fine example of translating variome data to the clinic. Here, we will discuss prototype hereditary ectopic calcification diseases with respect to their presentation, diagnosis and management.

De Vilder EYG *,* Vanakker OM. From variome to phenome: Pathogenesis, diagnosis and management of ectopic mineralization disorders. *World J Clin Cases* 2015; In press

**INTRODUCTION**

Physiological biomineralization is a complex multifactorial metabolic process, which in normal conditions is restricted to the extracellular matrix (ECM) of specific body structures, namely the bones, teeth, hypertrophic growth plate cartilage and calcified articular cartilage[1,2]. The intracellular and extracellular mechanisms, underlying physiological biomineralization, rely on a balanced interplay between mineralization inhibitors and propagators (Figure 1)[2,3]. Although in physiological circumstances calcium and inorganic phosphate (Pi) concentrations exceed their solubility in most human tissues, this does not result in mineralization of soft tissues, suggesting that these tissues possess regulatory mechanisms preventing mineral deposition. Mineralizing tissues must be able to modulate these mechanisms to enable calcification [2], but should also contain anti-mineralizing factors to prevent escalation of the calcification process leading to excessive and uncontrolled mineral deposits[1,2]. When these regulatory mechanisms are inadequate, ectopic mineralization, *i.e.,* inappropriate biomineralization in soft tissues, occurs and causes a spectrum of ectopic calcification disorders (Table 1)[2,4].

Uncontrolled mineralization occurs frequently in response to tissue injury or a systemic mineral imbalance. This leads to the development of a calcified lesion, which can occur throughout the body, though tissues as articular cartilage, the cardiovascular (CV) tissues and kidneys seem particularly prone[3,5,6]. Unlike physiological mineralization deposits, which only contain calcium phosphate crystals such as hydroxyapatite, ectopic mineralization depositions may also contain other calcium salts, including calcium oxalates or octacalcium[4].

Regarding the initiation of and pathogenetic mechanisms underlying ectopic mineralization several hypotheses have been proposed (Figure 1): (1) Increasing evidence is found that soft tissue calcification can be initiated in matrix vesicles (MVs), extracellular membrane particles (approximately 20-200 nm in diameter), which have a key role in the normal physiological mineralization process[3]. MVs contain calcium-binding non-collagenous matrix proteins, such as secreted phosphoprotein 1 (SPP1; OMIM\*166490), which can boost mineralization *in vitro*[7]. MVs initiate mineralization in 2 phases: Initial formation of hydroxyapatite in the MV itself: after budding from the plasma membrane, tissue-nonspecific alkaline phosphatase (TNAP; OMIM\*171760) activity induces an increase of extracellular Pi concentration, which then enters the vesicles via sodium-dependent inorganic phosphate transporters (PiTs). This is followed by calcium influx into the MVs, which is enabled by annexin A5 (ANXA5; OMIM\*131230) and phosphatidyl serine (PS), located at the MV inner membrane leaflet[1,3], Propagation of the calcium salts in the ECM: in the MVs hydroxyapatite crystals continue to grow, eventually rupturing the MV membrane. As a result, the crystals are exposed to the ECM, inducing their further expansion[3,8]; (2) Pathological calcification can also be influenced by ectopic osteogenic and chondrogenic signaling, leading to the activation of multiple pro-mineralization proteins[9]. This conversion of tissue-specific cells to bone-like cells has been mainly described in vascular calcification, and is probably due to the common mesenchymal origin of vascular smooth muscle cells (VSMCs) and bone cells[1]; (3) Apoptosis or programmed cell death is accompanied by the release of apoptotic bodies, which exteriorize PS to the outer membrane of the apoptotic body and therefore face the ECM. There, PS may bind calcium, resulting in an accumulation of calcium and phosphate, as is also seen in MVs, thus contributing to physiological and pathological mineralization[1,10]. Another potential apoptosis pathway includes elevated phosphate levels to induce VSMC apoptosis, a process that is possibly caused by downregulation of growth arrest-specific 6 (Gas6; OMIM\*600441) and B-cell CLL/Lymphoma (BCL2; OMIM+151430), with subsequent caspase 3 activation[11,12]; and (4) Reactive oxygen species (ROS), highly reactive oxygen-containing molecules, are formed as byproducts of normal oxygen metabolism and has important roles in cell signaling and metabolism. Nonetheless, if ROS concentration surpasses a critical threshold, oxidative stress, accompanied by important cell damage, can occur[13]. Potential sources of ROS in soft tissues are nicotinamide adenine dinucleotide (phosphate) [NAD(P)H] oxidase, nitric oxide synthase (NOS), xanthine oxidase, cytochrome P450 and cyclooxygenase; in addition, mitochondrial dysfunction may also lead to the formation of ROS. ROS possibly causes soft tissue mineralization through either the IκB-NF-κB pathway (inhibitor of kB - nuclear factor kappa-light-chain-enhancer of activated B cells), upregulation of the pro-osteogenic bone morphogenetic protein 2 (BMP2; OMIM\*112261) pathway and/or osteogenic conversion of soft tissue cells[1].

These pathophysiological mechanisms are however not mutually exclusive and display significant crosstalk[1].

Ectopic soft tissue mineralization is a common finding in aging and several common disorders, including atherosclerosis, hypertension, diabetes, chronic kidney disease and autoimmune diseases, and can be related to significant morbidity and mortality in each of these. It has been shown that vascular calcification correlates with an increased risk of myocardial infarction and that it is an independent risk factor for death in patients with coronary artery calcification[14,15]. However, in these complex, multifactorial disorders, multiple genes are likely to contribute, with each gene having only a small effect[16]. Contrary, in primary genetic mineralization disorders mutations in a single gene or few genes can cause an often extreme and life-threatening phenotype. Though individually rare, as a group they affect a considerable number of patients with important impact on quality of life and high morbidity and mortality rates.

Ectopic mineralization disorders are conventionally classified based on the mechanism through which the mineralization takes place: *i.e.,* metastatic or dystrophic calcification or ectopic ossification (Table 1)[14]: (1) Metastatic calcification, due to hyperphosphatemia and/or hypercalcemia; (2) Dystrophic calcification, which occurs in diseased (metabolically impaired or dead) tissue under normal calcium and phosphate homeostasis[1]; and (3) Ectopic or heterotopic ossification, leading to true bone formation[1,4,17,18].

For many of these disorders, important advances have been made in defining their clinical presentation (phenome), their (molecular) etiology (variome) and the correlation between both. This has led to novel insights and perspectives for the management and treatment of the patients, but also supports the complexity of the pathophysiology of soft tissue mineralization.

This review will focus on the clinical presentation, pathogenesis and management of primary genetic soft tissue mineralization disorders due to dystrophic (Pseudoxanthoma elasticum, Generalized arterial calcification of infancy, Keutel syndrome, Idiopathic basal ganglia calcification, Arterial calcification due to CD73 deficiency) or metastatic calcification (Hyperphosphatemic familial tumoral calcinosis).

**PSEUDOXANTHOMA ELASTICUM**

Pseudoxanthoma elasticum (PXE; OMIM#264800) is a rare, autosomal recessive connective tissue disorder, resulting from ectopic mineralization and fragmentation of elastic fibers. The prevalence of PXE is estimated between 1/25.000 and 1/100.000 with a carrier frequency of 1/80, although this may be an underestimation due to the variability of the phenotype, which in some cases may hinder the diagnosis[19-21].

***Clinical characteristics***

PXE primarily affects 3 organ systems, *i.e.,* the skin, the eyes and the CV system, albeit with important inter- and intrafamilial variability in severity[19,21,22]. Usually the skin symptoms are the first to arise, though they are not present in all patients, presenting as soft yellowish papules in flexural body areas (*i.e.,* neck, axilla, elbow, groin and knees) (Figure 2A-E)[19]. These solitary papular lesions can coalesce into larger plaques. Loss of resilience may give the skin a wrinkled aspect and can cause an esthetic burden[1,19]. Less frequently, mucosal lesions (usually at the inner lower lip) are present (Figure 2F)[19]. The emergence of additional inelastic skin folds [1], especially in neck (and thigh) area(s) can also cause functional problems, *e.g.,* when sleeping or riding a bicycle[1,19].

The most common ocular features in PXE patients are peau d’orange and angioid streaks (AS), which themselves cause no functional impairment (Figure 2G). In later stages choroidal (subretinal) neovascularization (CNV) occurs and these neovessels may rupture, causing retinal hemorrhage (Figure 2I). Symptoms will include metamorphopsia and vision loss, which can be permanent if left untreated. More recently, chorioretinal atrophy, subretinal fluid independent from CNV, pattern dystrophy-like changes, debris accumulation under the retinal pigment epithelium (RPE), reticular drusen and a decreased fluorescence on late phase indocyanine green (ICG) angiography were described[23].

CV symptoms, usually arising when patients are 30-40 years old, include accelerated coronary and peripheral artery disease (hypertension, myocardial infarction, intermittent claudication), diastolic cardiac dysfunction and gastrointestinal hemorrhage[24]. In 15% of PXE patients ischemic stroke may occur, at an average age of 49[1,24]. Heterozygous carriers usually develop neither skin nor eye symptoms but can suffer from accelerated atherosclerosis and (mild) diastolic dysfunction of the heart[24].

To date, no correlation has been established between the PXE phenotype and mutations in the main causal gene adenosine triphosphate (ATP)-binding cassette, subfamily C, member 6 (*ABCC6*; OMIM\*603234), which complicates the prediction of the evolution and severity of the symptoms in an individual patient[19,25]. The absence of a reliable genotype-phenotype correlation suggests that other genes, so-called modifier genes, may play an important role in influencing the disease course, apart from other factors such as lifestyle, environmental factors and - although less probable - dietary habits[19]. Thus far, only one promising modifier gene, vascular endothelial growth factor A (*VEGFA*; OMIM+192240) has been identified for the PXE retinopathy[26].

***Pathogenesis***

PXE is caused by mutations in the *ABCC6* gene, encoding an ATP-binding efflux transporter, the substrate and (patho)physiological role of which are yet to be elucidated[27]. The ABCC6 transporter is mainly expressed in the liver and kidneys while only minimally present in the organs affected by PXE[28,29]. This led to the hypothesis that PXE is a metabolic disorder in which a defective transporter causes inefficient transport of one or multiple substrates into the bloodstream[28,29]. As a result, a deficiency of vitamin K (VK) -dependent and -independent mineralization inhibitors occurs, favoring ectopic soft tissue mineralization[23,30,31]. The metabolic hypothesis was reinforced several times, until very recently Ziegler *et al*[32] reported that a conditional, liver-specific *Abcc6*-/- mouse model does not develop ectopic mineralization and concluded that mineralization in PXE occurs through a liver-independent mechanism. This would correspond with a second, so-called cellular, hypothesis which states that the local environment in the affected organ systems is altered; in this respect it was shown that PXE fibroblasts suffer mild chronic oxidative stress because of overexpression of oxidative stress-favoring mediators[31,33].

More recently, 3 pro-osteogenic pathways, *i.e.,* BMP2-Smad (mothers against decapentaplegic, drosophila, homolog of; OMIM\*601366)- runt-related transcription factor 2 (RUNX2; OMIM\*60021) and transforming growth factor β2 (TGFβ2; OMIM\*190220)-Smad2/3 pathways and the MSX2 (muscle segment homeobox, drosophila, homolog of, 2; OMIM\*123101)-canonical WNT (wingless-type MMTV integration site family; OMIM\*164820) pathway which are associated with vascular mineralization, were found to be upregulated in the skin and eyes of PXE knock-out mice and in PXE patients (Figure 1)[34]. The relevance of BMP2-Smad-RUNX2 signaling was alluded on by previous observations in PXE, including the low levels of carboxylated (active) matrix gla protein (MGP*;* OMIM\*154870)/gamma-carboxyglutamic acid, a potent inhibitor of BMP2, the upregulation of several target genes of RUNX2 such as SPP1, osteocalcin, matrix metalloproteinase (MMP9; OMIM\*120361), TNAP and VEGFA, the influence of oxidative stress on BMP2 expression and the overexpression of RUNX2 in calcified cardiac tissue of the *Abcc6*-related dystrophic cardiac calcification (DCC) mouse[34-36]. Furthermore, apoptosis was identified as an important process in PXE contributing to mineralization, by activation of BCL2 and multiple caspases[34].

Some insights in the dysfunction of pro- and anti-mineralizing factors in the PXE pathogenesis, have been described in the PXE murine model and/or PXE patients. Several local pro-mineralizing factors seem to be upregulated *in vitro* and/or *in vivo* (TNAP, BMP2) while mineralization inhibitors, such as ecto-5-prime-nucleotidase or CD73 (NT5E; OMIM\*129190), SPP1, ankyrin (mouse, homolog of) (ANKH; OMIM\*605145) and VK-dependent calcification inhibitors, were found to be less expressed[37-39].

Besides local factors, systemic inhibitors of mineralization such as Fetuin A and more recently inorganic pyrophosphate (PPi), were shown to be less abundant in PXE. PPi is a potent endogenous inhibitor of vascular calcification, both *in vitro* and *in vivo*, which was already shown to be downregulated in PXE fibroblasts, thus promoting pro-calcifying stimuli leading to tissue mineralization[40,41]. Jansen *et al*[42] found low PPi serum levels in both *Abcc6*-/- mice and PXE patients, and concluded that an impaired ABCC6 transporter negatively influences PPi efflux from hepatocytes to the hepatic circulation, though the exact mechanism is poorly understood.

***Diagnosis***

The diagnosis of PXE is a clinical one to begin with, based on the presence of typical skin and/ or fundus changes. While the skin lesions of PXE can be mimicked macroscopically by other disorders (Table 2), the presence of peau d’orange and/or AS in the ocular fundus can be considered pathognomonic. Diagnostic confirmation can be obtained by skin biopsy, showing shortened, fragmented elastic fibers as well as mineral deposits in the mid-dermis using H&E (hematoxylin and eosin) and von Kossa staining. Molecular analysis of the *ABCC6* gene will detect both causal mutations in approximately 95% of patients[1,33,43,44]. Sanger sequencing is still the gold standard, but should be complemented with multiplex ligation-dependent probe amplification (MLPA), to detect larger deletions and insertions[45]. If no or only one *ABCC6* mutation can be identified, it is worthwhile to screen for gamma-glutamyl carboxylase (*GGCX*; OMIM\*137167) mutations as digenic inheritance has been described[46]**.** Furthermore, the initial presentation of the *GGCX*-related PXE-like disorder with coagulation factor deficiency (see below) can be identical to PXE[47,48]. Sequencing of the ectonucleotide pyrophosphatase/phosphodiesterase 1 (*ENPP1*; OMIM\*173335) gene is useful when no *ABCC6* mutations can be detected in a patient with a histologically confirmed diagnosis of PXE; digenic inheritance of an *ABCC6* and *ENPP1* mutation has so far not been reported[49]. This increasing number of genes which may cause PXE as well as the potential importance of modifier genes, brought about a gradual shift from Sanger sequencing towards the more recently introduced next generation sequencing[26,47,50-52].

***Differential diagnosis***

The differential diagnosis of PXE manifestations is summarized in Table 2.

***Management***

To date, PXE management is mainly symptomatic, focusing on prevention and treatment of complications[19]. For ophthalmological complications, preventive measures include wearing glasses and avoiding sports and activities with a (relative) high risk of (head) trauma or increased pressure[19,21,60]. Once fundus changes have appeared, an annual control by an ophthalmologist is important, as well as weekly self-examination using the Amsler Grid. If distortion or metamorphopsia occurs, the patient should contact his/her ophthalmologist immediately[20,23]. Timely treatment with anti-VEGF antibodies, such as bevacizumab or ranibizumab, were shown to be successful in forcing back neovessels and preserving visual acuity[1,20,30]. Prophylactic anti-VEGF therapy has however not been proven to be advantageous[19].

The prevention of CV complications consists of controlling traditional CV risk factors (*e.g.,* smoking, obesity, hypercholesterolemia and diabetes)[1]. Upon diagnosis, a baseline screening should be performed with measurement of blood pressure, assessment of biochemical CV risk factors, echocardiography, determination of the ankle-brachial index and duplex ultrasound of the arteries of the neck and lower extremities. If hypertension is found, further assessment with 24-h blood pressure monitoring and an exercise test should be done. Further CV management is tailored based on the results of this screening, usually comprising an annual checkup by a cardiologist and if necessary initiation of secondary prevention[24]. Since heterozygous carriers suffer CV complications more frequently compared to the general population, they should also undergo a baseline CV screening and regular checkups by a cardiologist[24]. Furthermore, the use of anticoagulants, aspirin and nonsteroidal anti-inflammatory drugs should be avoided as they may elevate the risk of gastrointestinal bleeding[1]. When complications do occur, standard interventional or surgical procedures can usually be applied[24,61].

For the skin problems no prevention is possible and therapeutic options are scarce. When functional problems arise, mainly due to excessive skin folds, plastic surgery can be attempted [61]. Possible post-surgery complications include slower wound healing and apparition of skin lesions in the scars[61-63]. Recently, Salles *et al*[64] described a PXE patient in which skin lesions in the neck were successfully treated with fractional carbon dioxide laser therapy. The post-laser reaction - redness, pain, swelling and crusting - was the same as seen in normal skin. After a follow-up of 2 years, the treatment showed an overall satisfactory esthetic result, showing improvement of the skin texture, irregularity, volume and distensibility. Moreover, lipofilling to reduce esthetically disturbing skin folds, especially in the neck region, is being evaluated in an experimental setting[65].

# PXE-LIKE SYNDROME WITH MULTIPLE COAGULATION FACTOR DEFICIENCY

In 2007, Vanakker *et al*[1,47] described a new autosomal recessive disorder which was closely related to PXE and coined it the PXE-like syndrome with multiple coagulation factor deficiency (OMIM#610842). To date, the disorder has been described in 12 patients, 8 of which had molecular confirmation of the clinical suspicion[47,48,66-68].

*Clinical characteristics*

The initial presentation of the PXE-like syndrome is nearly identical to that of PXE, making it often difficult to distinguish the two diseases in young adults. The natural evolution of the PXE-like disorder is however completely different and characterized by severe cutaneous symptoms with the development of thick and redundant skin folds, not restricted to flexural areas but variably expanding toward limbs and abdomen (Figure 3), a mild retinopathy and a deficiency of the VK-dependent coagulation factors (coagulation factors II, VII, IX, X)[1,47,48]. Furthermore, subclinical atherosclerosis and cerebral aneurysms have been described[47].

***Pathogenesis***

Biallelic mutations have been described in the *GGCX* gene, encoding a gamma-carboxylase enzyme which performs an essential post-translational modification step of a number of so-called VK-dependent proteins, including clotting factors and mineralization inhibitors (Figure 1). It was shown that the PXE-like mutations result in a reduced activity of the enzyme, thus leading to inadequate carboxylation (or activation) of these VK-dependent proteins. This causes a deficiency of coagulation factors and creates an environment which favors ectopic mineralization [1].

***Diagnosis***

The diagnosis of PXE-like syndrome is relatively straightforward when typical skin lesions are seen in combination with a deficiency in the VK-dependent clotting factors. Biochemically, a prolonged prothrombin time can be found, though the coagulation factor deficiency can be very mild[47]. In young individuals, the diagnosis should be considered in every patient suspected of having PXE in whom no *ABCC6* mutations are found. Histopathology shows fragmentation and calcification of the middermal elastic fibers, being located in the periphery of the fiber[69]. Light microscopy will not allow differentiating with PXE, but on electron microscopy the elastic fibers are more ragged and the calcification is located in the periphery of the fibers (compared to fiber core mineralization in PXE). The diagnosis can be confirmed by *GGCX* sequencing[47].

***Differential diagnosis***

The differential diagnosis of PXE-syndrome is summarized in Table 3.

***Management***

The management of PXE-like patients is similar to that of patients with classic PXE. In most, treatment of the coagulation deficiency is not necessary, though the use of anticoagulants is not advised. In rare cases, supplementation with VK may be useful[47].

# GENERALIZED ARTERIAL CALCIFICATION OF INFANCY

Generalized arterial calcification of infancy (GACI; OMIM#20800) is an early-onset, autosomal recessive disorder, which has only been described in approximately 100 mostly Caucasian patients[1,70]. The disease typically affects infants of less than 6 months of age[71,72].

***Clinical characteristics***

GACI is characterized by arterial stenosis, resulting from myointimal proliferation of muscular arteries, and early-onset severe myocardial ischemia due to extensive deposition of hydroxyapatite in the inner elastic lamina of medium- and large-sized arteries[1,70,73]. Complications include myocardial infarction, hypertension and congestive heart failure, leading to early demise [1]. Other possible manifestations include dermatological and ophthalmological findings typical of PXE, extravascular (mostly periarticular) calcifications, hearing loss and development of hypophosphatemic rickets after infancy[49,70,71,74-77]. The majority of patients die before the age of 1, with the highest fatality rate in the first six months of life, most commonly due to myocardial infarction, congestive heart failure, multiple organ failure or persistent arterial hypertension[71,72]. Recently, Rutsch *et al*[71] reported a mortality rate of 55%, with a marked decrease in the mortality of patients, which survived the first 6 mo. In some of these, spontaneous resolution of the mineralization was seen[78,79].

***Pathogenesis***

GACI is caused by inactivating mutations in the *ENPP1* gene, which encodes ectonucleotide pyrophosphatase/phosphodiesterase 1. Under normal conditions, ENPP1 is associated with the outer plasma membrane of VSMCs in arteries and generates extracellular PPi through hydrolysis of ATP to adenosine monophosphate (AMP)[2]. PPi is a potent calcification inhibitor, which was already shown to hinder mineral crystal growth by binding to the crystal surface in osteoblast cultures [1,2,17].

***Diagnosis***

Neonates with GACI can present with rather aspecific symptoms, such as poor feeding and respiratory distress. Consequently the diagnosis is often only established by detecting arterial calcification using plain radiography, ultrasound or computed tomography. Typically, diffuse vascular and periarticular ectopic mineralization is found. GACI should be considered antenatally when ultrasonographic anomalies include arterial calcifications, hydrops, abnormal cardiac contractility and/or hyperechoic kidneys[80]. Confirmation of the diagnosis is possible through molecular analysis of the *ENPP1* gene which detects mutations in approximately 70% of cases[49,71,81,82]. When no mutations can be found in *ENPP1*, *ABCC6* sequencing should be performed, due to an overlap in the phenotypes of both diseases[70,73]. An arterial biopsy shows fragmentation in the integral elastic lamina with calcium deposition and fibrointimal hyperplasia causing luminal narrowing, which can occur in places devoid of mineralization[72,83]. Conversely, mineralization can occur without luminal narrowing[84]. Apart from calcium, the depositions also contain iron and mucopolysaccharides[84,85]. The lesions are surrounded by a giant cell reaction[86].

***Differential diagnosis***

The differential diagnosis of GACI is summarized in Table 4.

***Management***

The treatment options in GACI are limited and rely mostly on the use of bisphosphonates, such as etidronate and pamidronate, which are analogs of PPi. These bisphosphonates possibly act through decreasing bone turnover, inhibiting further growth of mineralized crystals and/or providing an alternative form of PPi that may influence the regulation of mineralization[91]. Vascular calcifications have been reported to disappear under bisphosphonate therapy within a variable time period (2, 5 wk to 2 years). Calcifications do not tend to reappear after cessation of the therapy, although arterial stenosis persists[92,93]. Since prolonged etidronate use in GACI patients has been linked to severe skeletal toxicity, bisphosphonate therapy should be closely monitored and according to some, should be stopped as soon as the calcifications have disappeared[94]. Nevertheless, the prognosis of patients remains poor with only few long-term survivors, the oldest GACI patient being 25[1,71,79,95]. Recently, Towler *et al*[96] suggested that restoring PPi levels by inhibition of alkaline phosphatase (ALP) and/or upregulation of vascular ENPP1 or ANKH-mediated secretion of intracellular PPi may serve as possibilities to limit vascular calcification.

**KEUTEL SYNDROME**

Since its first identification by Keutel *et al*[97,98] in 1971, approximately 30 cases have been described of Keutel syndrome (OMIM#245150), which is an autosomal recessive multisystem disease with an age of onset in childhood (5-15 years).

***Clinical characteristics***

Keutel syndrome is mainly characterized by peripheral pulmonary stenosis, abnormal cartilage ossification or calcification of typically (para)tracheal, bronchial and rib cartilages as well as auricular and nose cartilage[99]. Less frequently soft tissue calcification, *i.e.,* of blood vessels, brain and kidneys, occurs[1]. Other clinical features include CV (ventricular septal defect, pulmonary artery hypoplasia, hypertension)respiratory (recurrent respiratory infections), skeletal (brachytelephalangism, typically sparing the 5th distal phalanx, height below the 25th percentile), neurological symptoms (subnormal intelligence quotient (IQ) in multiple cases) and recurrent otitis media causing inner ear or mixed deafness. Patients have a typical facial gestalt with mild midface hypoplasia, a depressed nasal bridge, small alae nasi and a deep philtrum[100-104]. A long-term follow-up of 4 sisters with Keutel syndrome showed that all clinical manifestations were progressive. Further, these patients developed skin lesions, *i.e.,* multiple erythematous, irregularly bordered macular lesions without induration, typically after the age of 30. Skin biopsy of these lesions failed to show calcification or ossification and loss of elastic fibers was only seen in the papillary dermis[99]. Nevertheless, the prognosis of Keutel syndrome is good in the majority of patients, with life expectancy mainly depending on the severity of the pulmonary complications[99].

***Pathogenesis***

Keutel syndrome is caused by loss-of-function mutations in the *MGP* gene, encoding matrix gla protein [1]. MGP is an inhibitor of the pro-osteogenic BMP2-Smad-RUNX2 pathway, by inhibiting BMP2 to bind to its receptor. Consequently, MGP, expressed in chondrocytes, functions as a local mineralization inhibitor under physiological conditions (Figure 1)[105,106]. Impairment of its inhibitory function favors pro-mineralizing signaling, leading to ectopic mineralization[98]. Moreover, Cranenburg *et al*[107] reported a patient in whom the levels of carboxylated/uncarboxlated MGP were very low, unresponsive to VK supplementation, but in whom high levels of phosphorylated MGP were found. Phosphorylation is a VK-independent posttranslational modification of MGP which may allow binding of calcium crystals in the absence of optimal carboxylation. It was hypothesized that this phosphorylation-dependent residual MGP activity might be sufficient to prevent development of arterial calcification[108].

***Diagnosis***

The majority of Keutel syndrome patients are diagnosed during childhood based on clinical presentation and radiographic examinations, with abnormal cartilage calcification and brachytelephalangism as major signs. The clinical diagnosis can be confirmed by sequencing of the *MGP* gene, in which to date 7 loss-of-function mutations have been reported [98,104,109].

***Differential diagnosis***

The differential diagnosis of Keutel syndrome is summarized in Table 5.

***Management***No etiologic treatment exists for Keutel syndrome, hence management is merely symptomatic, including (angiographic) dilatation of peripheral artery stenosis and bronchodilating agents for respiratory symptoms (dyspnea and wheezing); the latter however can be inefficient in certain patients[99,108]. Most patients develop hypertension before the age of 20, which can be treated with antihypertensive medication such as perindopril, amlodipine or nifedipine[99].

# IDIOPATHIC BASAL GANGLIA CALCIFICATION

# Idiopathic basal ganglia calcification (IBGC) is a rare neurodegenerative disorder with unknown prevalence. The disease is sometimes referred to as Fahr’s disease, although the patient he described primarily had mineralization in blood vessels of the white matter of the brain[113]. IBGC affects young to middle aged adults, with an average onset in the 3rd or 4th life decade; however the disease has also been described in childhood[114-116].

***Clinical characteristics***

IBGC is characterized by bilateral and (almost) symmetrical basal ganglia calcifications (Figure 4)[116]. Ectopic mineralization may also occur in other brain regions, including the nucleus dentatus, thalamus, cerebral cortex and centrum semiovale[116,117]. Neurological symptoms include neuropsychiatric (cognitive impairment, depression, hallucinations, delusions, manic symptoms, anxiety, schizophrenia-like psychosis, personality changes) and movement disorders (*a.o.* parkinsonism, ataxia due to cerebellar involvement, tremor and paresis), as well as headache, vertigo, stroke-like events, orthostatic hypotension, dysarthria, seizures and papilledema due to raised intracranial pressure[116,118]. Both sporadic and familial IBGC cases have been reported, the latter predominantly with autosomal dominant inheritance [116].

***Pathogenesis***

To date, mutations in 3 genes have been associated with IBGC, *i.e.,* solute carrier family 20 (phosphate transporter), member 2 (*SLC20A2*; OMIM\*158378), the beta polypeptide of platelet-derived growth factor (*PDGFB*; OMIM\*190040) and platelet-derived growth factor receptor, beta (*PDGFRB*; OMIM\*173410). So far, no genotype-phenotype correlation has been found[119]. The *SLC20A2* gene, encoding a Pi transporter (also known as PiT2 which belongs to the type III sodium-dependent phosphate transporter family), is expressed abundantly in a variety of tissues and likely plays a housekeeping role in cellular phosphate uptake (Figure 1)[119,120]. Mutations in the gene have been described in more than 40 IBGC families worldwide and *in vitro* resulted in impaired Pi transport, leading to accumulation of this pro-mineralizing factor[119,121,122].

More recently, a few IBGC patients were reported harboring mutations in *PDGFB* or *PDGFRB*[123-128]. In animal models, *Pdgfrb* has been identified as an essential mediator in the development of pericytes in brain vessels, which have a key role in the maintenance of the blood-brain barrier (BBB). The BBB is hypothesized to be defective in IBGC[123]. Moreover, Villa-bellosta *et al*[129] found that the PDGFB-PDGFRB pathway seems to be involved in phosphate-induced calcifications in VSMCs by downregulating SLC20A2. All these data suggest that cerebral phosphate homeostasis plays a role in the development of vascular mineralization[129]. The mineralization generally develops within the vessel wall and in the perivascular space, ultimately extending to the neuron. Upon progression, the calcifications start to compress the vessel lumen, which causes impaired blood flow, starting off a vicious circle with further neural tissue damage and mineral deposition. The mineral depositions tend to vary in composition according to their anatomical site and the proximity to vasculature calcifications, containing components such as calcium phosphate and carbonate; other compounds including glyconate, mucopolysaccharide and metals (iron, copper, magnesium, zinc, aluminum, silver and cobalt) may also be found[116]. Abnormal iron metabolism in IBGC has been described in a single case, showing elevated serum ferritin, reduced levels of serum iron and iron-binding capacity. At autopsy iron depositions were found in the liver, the spleen, the bone marrow and the brain[130]. More recent reports confirm abnormalities in metal metabolism (iron, copper, zinc), although there is no consensus whether the metal levels are elevated (cerebrospinal fluid) or reduced (hair) in IBGC patients[131,132].

***Diagnosis***

IBGC diagnosis is supported by the following criteria: (1) bilateral calcification of basal ganglia; (2) progressive neurologic dysfunction; (3) absence of biochemical abnormalities; (4) absence of infectious, traumatic of toxic cause; and (5) a significant family history (although sporadic IBGC cases have also been described)[116].

However, the diagnosis can only be established by obtaining a CT (computed tomography) or MRI (magnetic resonance imaging) scan of the brain, showing bilateral, almost symmetric calcifications of one or more of the affected brain regions, and ruling out other abnormalities (showing bilateral basal ganglia calcifications, and developmental defects)[116,133-136]. Other possible investigations, which are typically normal in IBGC patients, include blood and urine testing for hematologic and biochemical (ALP, serum creatinine, osteocalcin, serum lactic acid at rest and after exercise, 1,25-dihydroxyvitamin D3, serum calcium, phosphorus, magnesium, calcitonin, heavy metals and parathyroid hormone (PTH)) parameters and an Ellsworth Howard test (showing a 10-20 fold increase of urinary 3’-5’-cyclic adenosine monophosphate (cAMP) after stimulation with 200 U of PTH)[116,137-139]. Neurological tests are usually normal (electroencephalography, nerve conduction studies, pattern shift visual-evoked potential studies) or show mild abnormalities (brainstem auditory-evoked potentials)[116].

Genetic testing can confirm the IBGC diagnosis. Sequencing of *SLC20A2* is the first choice, as well as deletion/duplication analysis if no mutation is found, with a mutation detection rate of 40%. If no mutations are found, *PDGFRB* and *PDGFB* sequencing can be performed; the precise mutation detection rate is currently unknown. If no molecular confirmation can be obtained, other (genetic) causes of brain calcification should be considered (Table 6), before establishing a clinical diagnosis of IBGC[116].

***Differential diagnosis***

Symmetrical calcifications of the basal ganglia are not specific to IBGC and a variety of familial and non-familial conditions should be considered. It should be noted that these calcifications can also be incidental findings on CT scan, especially in older individuals (Table 6)[116,140].

***Treatment***

Since no etiologic treatment is available, management and treatment options focus on symptomatic relief[116,117,120]. Pharmacologic treatment (*e.g.,* anxiolytics and antidepressants) for the psychiatric and movement symptoms can be attempted[117,120]. Possibly, an early causative treatment may reverse the calcification process, causing complete recovery of mental functions, which was already described in hypoparathyroidism, another basal ganglia causing disorder, provided that an intervention target can be identified[116].

# ARTERIAL CALCIFICATION DUE TO CD73 DEFICIENCY

Arterial calcification due to CD73 deficiency (ACDC), also referred to as calcifications of joints and arteries, is an autosomal recessive disease, which usually takes an onset in young adulthood[16,144].

***Clinical presentation***

ACDC is mainly characterized by prominent and often symptomatic calcification of the large arteries of the lower extremities (iliac, femoropopliteal and tibial arteries), typically sparing the coronary circulation[16,144]. Furthermore, periarticular calcifications of (large and smaller) joints of the lower extremities have been described[144]. Typical symptoms include claudication, hemodynamically significant peripheral obstructive artery disease of the lower limbs, joint swelling and pain[144]. The disease seems relatively rare, being only reported in 3 Caucasian families[144,145].

***Pathogenesis***

To elucidate the molecular etiology of ACDC, genome-wide homozygosity mapping was performed in three families, revealing homozygous and compound heterozygous loss-of-function mutations in the *NT5E* gene[144,145]. *NT5E* encodes the glycosyl phosphatidylinositol (GPI)-linked plasma membrane CD73 ecto-enzyme, which has 5’ ectonucleotidase activity and thus converts AMP to extracellular adenosine and Pi[146]. The enzyme is located on the plasma membrane of vascular cells, supplying adenosine to cell surface receptors [145]. Adenosine is produced immediately downstream of ENPP1 in the extracellular ATP-degradation pathway on the surface of vascular cells, and a lower adenosine level leads to impaired inhibition of TNAP[16,144]. Hilaire *et al*[144] hypothesized that increased TNAP activity reduces PPi levels, allowing calcification to occur (Figure 1). Since the vascular calcification in ACDC seems to be limited to the lower extremities, it is likely that members of other ectonucleotidase families, such as ectonucleoside triphosphate diphosphohydrolase 1 or CD39 (*ENTPD1*; OMIM\*601752) and its isoforms or cardiac ectonucleoside triphosphate diphosphohydrolase 6 or CD39L2 (*ENTPD6*; OMIM\*603160) (members of the ectonucleoside triphosphate diphosphohydrolase (E-NTPDase) family), may compensate NT5E activity in other vascular beds[16,147]. An alternative explanation for this predilection may be the particular distribution of adenosine receptors in these vascular beds[148].

***Diagnosis***

An ACDC diagnosis can be established based on clinical presentation and a full radiographic workup of the patients, as well as determination of the ankle-brachial index, which should be reduced. Plain radiography can visualize the vessel calcifications; MR (magnetic resonance) angiography and especially CT angiography can show diffuse and gross calcification of obstructing lesions. Biochemical indices, including serum electrolytes, cholesterol and vitamin D-levels, PTH, C-reactive protein, rheumatoid factor and erythrocyte sedimentation rate should all be normal. The clinical suspicion can be confirmed by *NT5E* sequencing[144].

***Differential diagnosis***

Other - often not - hereditary causes of vascular calcification have to be excluded, *e.g.,* diabetes mellitus type 2 and impaired renal function[144]. Since joint swelling and pain was present in all three described families, rheumatologic diseases should also be excluded[144].

***Management***

Because of the rarity of the disease, no treatment guidelines are available. Bisphosphonates, which were proven to be successful in GACI, possibly by restoring PPi levels, may also be a good treatment option in ACDC[91,144]. Adenosine deficiency could be addressed using dipyridamole, which inhibits its cellular reuptake *in vitro* and *in vivo*. Other possible therapeutic options include adenosine receptor agonists or direct TNAP inhibitors (*e.g.,* lansoprazole), all of which need to be further investigated[144].

# HYPERPHOSPHATEMIC FAMILIAL TUMORAL CALCINOSIS

# Contrary to the disorders described above, autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC; OMIM#211900), is characterized by metastatic mineralization[1,149]. Patients usually show first signs in the first or second decade of life[150].

***Clinical characteristics***

The most prominent clinical manifestation of HFTC is periarticular mineralization of the skin and subcutaneous tissue, mainly affecting the upper limbs and hip regions, although involvement of other localizations (spine, temporomandibular joints, metacarpals/metatarsals and popliteal space) have also been reported[151]. The calcium salt depositions usually present as firm painful tumorlike masses, which may gradually enlarge over a period of years, causing functional problems including restricted joint mobility[149,151]. Complications of the overlying skin, including pain, infection and ulceration, can cause scarring and deformity[1,149,151]. Other possible manifestations of the disorder are dental abnormalities and retinal AS[152].

***Pathogenesis***

HFTC can be caused by mutations in UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase 3 (*GALNT3*; OMIM\*601756), fibroblast growth factor 23 (*FGF23*; OMIM\*605380) or klotho (*KL*; OMIM+604824), all of which are key regulators of the phosphate metabolism[1]. GALNT3 protects intact FGF23, a phosphaturia-causing protein, from proteolytic processing by O-glycosylation of Threonine residue 178 in a subtilisin-like proprotein convertase (SPC) recognition sequence motif. In this way, FGF23 is activated and enabled to secrete from the cell, while this glycosilation also competitively inhibits proteolytic FGF23 cleavage by proteases. Hence, this glycosylation step is proposed to be a posttranslational regulatory model. In the presence of (nonsense/missense/splice-site) *GALNT3* mutations, intact FGF23 is cleaved prior to secretion which leads to an accumulation of fragmented FGF23 and a reduced amount of active FGF23, causing hyperphosphatemia[153,154]. In physiological conditions FGF23 binds to the FGF receptor 1, of which KL, a β-glucuronidase, is an important co-receptor, inducing high affinity interaction between FGF23 and its receptor. This activates the further downstream effects of this pathway, including the maintenance of serum phosphate levels within the normal range by increasing renal phosphate excretion and both a reduction of synthesis rate and acceleration of the degradation of 1,25-dihydroxivitamin D3 to reduce intestinal phosphate absorption (Figure 1)[155,156]. Moreover, KL works independently from FGF23 as an enzymatic inhibitor of renal NaPi-2a (sodium/phosphate cotransporter) transporter activity - which requires glucuronidase activity, subsequent proteolytic degradation and possibly internalization of the transporter - eventually leading to reduced renal expression of the transporter[157]. FGF23 fulfills its biological functions in a tissue-specific way, which is likely to be regulated by the limited local distribution of KL[155]. Inactivating mutations in FGF23 as well as missense mutations in KL cause FGF23 deficiency. Consequently renal phosphate reabsorption and 1,25-dihydroxyvitamin D3 synthesis is increased, leading to elevated serum concentrations of phosphate, 1,25-dihydroxyvitamin D3 and calcium and ectopic mineralization[155].

***Diagnosis***

Next to clinical examination and family history, the diagnosis of HFTC is mainly based on a full radiographic workup: (1) Plain radiographs show the typical appearance of periarticular amorphous, multilobulated and cystic calcifications[158]; (2) CT, showing cystic loculi with fluid-fluid levels caused by calcium layering; (3) MRI imaging, showing lesions of inhomogeneous intensity, help to document the extent and interconnectivity of individual lesions and can help to determine possible surgical approaches; (4) scintigraphy, using a phosphate compound radiolabel (technetium-99m methylene diphosphonate) is helpful in determining the activity level of the disease; and (5) ultrasonography can help to localize fluid collections[149]. A typical feature of HFTC is the absence of erosion/bone destruction by adjacent soft-tissue masses[149]. Biochemically, hyperphosphatemia with normocalcemia, normal or slightly elevated 1,25-dihydroxyvitamin D3, hypoparathyroidism and low intact FGF23 proteins levels can be found[152]. A biopsy should be avoided, because of the risk of an infection and should only be done as a last resort. Histopathology shows that mineralization depositions fill up the cystic loculi (active stage), which causes them to become encapsulated by fibrous tissue, eventually ending the mineralization process (relative latent stage)[150].

***Differential diagnosis***

The differential diagnosis of HFTC is summarized in Table 7.

***Management***

HFTC should be treated according to the location, size of the lesion and its relations to its environment. A first treatment option is medically reducing hyperphosphatemia through phosphate depletion, by dietary phosphorus restriction and/or the administration of phosphate binding chelating agents such as aluminum hydroxide. This method has a variable success rate, both in normo- and hyperphosphatemic cases. When combined with acetazolamide, which induces phosphaturia, a synergistic effect occurs, especially in the hyperphosphatemic form of familial tumoral calcinosis[149].

A second treatment option is early surgical resection of the lesions; however a considerable recurrence rate of the lesions, which have the tendency of growing faster, poses a major problem. Therefore it is very important that resections contain the lesion, and preferably should contain a wider perilesional area/band, including the hypervascular region beyond the periphery of the lesion. Broad resections can cause problems in case of voluminous lesions, which may require extensive reconstructive surgery[149]. Surgery is indicated when lesions are painful, recurrently infected, ulcerated or when functional impairment occurs[149]. Surgical complications include: (1) prolonged drainage of the wound, possibly leading to delayed wound healing and sinus tract formation; (2) secondary infections due to chronic wound problems, especially when the disease is extensive or when resection is incomplete; and (3) recurrence, which is more frequently seen after incomplete resection[167].

During the active stage of the disease, primary medical treatment of HFTC is justified and may even be recommended, because the postresection recurrence rate of lesions is even higher in this stage. In the relative latent stage, encapsulation occurs which hinders ion exchange, thus making surgery more advantageous[149]. Alternative treatment options, including steroids, bisphosphonates, calcitonin and radiotherapy, have not been proven to be effective[149].

**CONCLUSION**

Ectopic mineralization disorders comprise a wide range of heterogeneous diseases, which can affect a variety of tissues, causing important health problems. Insights in the mechanisms that cause these diseases have led to the observation that many - if not all - are closely related to one another from a mechanistic point of view. The considerable differences in clinical presentation and natural course however suggest that our current knowledge is merely the proverbial tip of the iceberg and that the subtle mechanisms which render each disease to be unique are still largely to be uncovered. Nevertheless, the pathophysiological knowledge to date has already led to several successful treatment options and a number of promising targets for the future. As such, ectopic mineralization diseases are a fine example for the interaction between the variome and the phenome.

**REFERENCES**

1 **Vanakker O,** Hosen MJ, De Paepe A. Ectopic soft tissue calcification: process, determinants and health impact. Hauppauge, NY: Human Anatomy and Physiology, 2013: 261-304

2 **Kirsch T**. Biomineralization--an active or passive process? *Connect Tissue Res* 2012; **53**: 438-445 [PMID: 22992051 DOI: 10.3109/03008207.2012.730081]

3 **Golub EE**. Biomineralization and matrix vesicles in biology and pathology. *Semin Immunopathol* 2011; **33**: 409-417 [PMID: 21140263 DOI: 10.1007/s00281-010-0230-z]

4 **Giachelli CM**. Ectopic calcification: gathering hard facts about soft tissue mineralization. *Am J Pathol* 1999; **154**: 671-675 [PMID: 10079244 DOI: 10.1016/S0002-9440(10)65313-8]

5 **Kornak U**. Animal models with pathological mineralization phenotypes. *Joint Bone Spine* 2011; **78**: 561-567 [PMID: 21550285 DOI: 10.1016/j.jbspin.2011.03.020]

6 **Kirsch T**. Determinants of pathological mineralization. *Curr Opin Rheumatol* 2006; **18**: 174-180 [PMID: 16462525 DOI: 10.1097/01.bor.0000209431.59226.46]

7 **Nahar NN**, Missana LR, Garimella R, Tague SE, Anderson HC. Matrix vesicles are carriers of bone morphogenetic proteins (BMPs), vascular endothelial growth factor (VEGF), and noncollagenous matrix proteins. *J Bone Miner Metab* 2008; **26**: 514-519 [PMID: 18758911 DOI: 10.1007/s00774-008-0859-z]

8 **Dean DD**, Schwartz ZV, Muniz OE, Gomez R, Swain LD, Howell DS, Boyan BD. Matrix vesicles contain metalloproteinases that degrade proteoglycans. *Bone Miner* 1992; **17**: 172-176 [PMID: 1611305 DOI: 10.1016/0169-6009(92)90731-R]

9 **Shanahan CM**, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. *Circ Res* 2011; **109**: 697-711 [PMID: 21885837 DOI: 10.1161/CIRCRESAHA.110.234914]

10 **Scull CM**, Tabas I. Mechanisms of ER stress-induced apoptosis in atherosclerosis. *Arterioscler Thromb Vasc Biol* 2011; **31**: 2792-2797 [PMID: 22096099 DOI: 10.1161/ATVBAHA.111.224881]

11 **Son BK**, Kozaki K, Iijima K, Eto M, Nakano T, Akishita M, Ouchi Y. Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells. *Eur J Pharmacol* 2007; **556**: 1-8 [PMID: 17196959 DOI: 10.1016/j.ejphar.2006.09.070]

12 **Collett G**, Wood A, Alexander MY, Varnum BC, Boot-Handford RP, Ohanian V, Ohanian J, Fridell YW, Canfield AE. Receptor tyrosine kinase Axl modulates the osteogenic differentiation of pericytes. *Circ Res* 2003; **92**: 1123-1129 [PMID: 12730092 DOI: 10.1161/01.RES.0000074881.56564.46]

13 **Lee J**, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. *Biochem J* 2012; **441**: 523-540 [PMID: 22187934 DOI: 10.1042/BJ20111451]

14 **Li Q**, Uitto J. Mineralization/anti-mineralization networks in the skin and vascular connective tissues. *Am J Pathol* 2013; **183**: 10-18 [PMID: 23665350 DOI: 10.1016/j.ajpath.2013.03.002]

15 **Nitschke Y**, Rutsch F. Genetics in arterial calcification: lessons learned from rare diseases. *Trends Cardiovasc Med* 2012; **22**: 145-149 [PMID: 23122642 DOI: 10.1016/j.tcm.2012.07.011]

16 **Rutsch F**, Nitschke Y, Terkeltaub R. Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. *Circ Res* 2011; **109**: 578-592 [PMID: 21852556 DOI: 10.1161/CIRCRESAHA.111.247965]

17 **Li Q**, Jiang Q, Uitto J. Ectopic mineralization disorders of the extracellular matrix of connective tissue: molecular genetics and pathomechanisms of aberrant calcification. *Matrix Biol* 2014; **33**: 23-28 [PMID: 23891698 DOI: 10.1016/j.matbio.2013.06.003]

18 **Edwards DS,** Clasper JC. Heterotopic ossification: a systematic review. *J R Army Med Corps* 2014 Jul 11; pii: jramc-2014-000277 [PMID: 25015927 DOI: 10.1136/jramc-2014-000277]

19 **Finger RP**, Charbel Issa P, Ladewig MS, Götting C, Szliska C, Scholl HP, Holz FG. Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. *Surv Ophthalmol* 2009; **54**: 272-285 [PMID: 19298904 DOI: 10.1016/j.survophthal.2008.12.006]

20 **Georgalas I**, Tservakis I, Papaconstaninou D, Kardara M, Koutsandrea C, Ladas I. Pseudoxanthoma elasticum, ocular manifestations, complications and treatment. *Clin Exp Optom* 2011; **94**: 169-180 [PMID: 21198842 DOI: 10.1111/j.1444-0938.2010.00559.x]

21 **Hu X**, Plomp AS, van Soest S, Wijnholds J, de Jong PT, Bergen AA. Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. *Surv Ophthalmol* 2003; **48**: 424-438 [PMID: 12850230 DOI: 10.1016/S0039-6257(03)00053-5]

22 **Christen-Zäch S**, Huber M, Struk B, Lindpaintner K, Munier F, Panizzon RG, Hohl D. Pseudoxanthoma elasticum: evaluation of diagnostic criteria based on molecular data. *Br J Dermatol* 2006; **155**: 89-93 [PMID: 16792757 DOI: 10.1111/j.1365-2133.2006.07278.x]

23 **Gliem M**, Zaeytijd JD, Finger RP, Holz FG, Leroy BP, Charbel Issa P. An update on the ocular phenotype in patients with pseudoxanthoma elasticum. *Front Genet* 2013; **4**: 14 [PMID: 23577018 DOI: 10.3389/fgene.2013.00014]

24 **Campens L**, Vanakker OM, Trachet B, Segers P, Leroy BP, De Zaeytijd J, Voet D, De Paepe A, De Backer T, De Backer J. Characterization of cardiovascular involvement in pseudoxanthoma elasticum families. *Arterioscler Thromb Vasc Biol* 2013; **33**: 2646-2652 [PMID: 23968982 DOI: 10.1161/ATVBAHA.113.301901]

25 **Vanakker OM**, Hosen MJ, Paepe AD. The ABCC6 transporter: what lessons can be learnt from other ATP-binding cassette transporters? *Front Genet* 2013; **4**: 203 [PMID: 24137173 DOI: 10.3389/fgene.2013.00203]

26 **Zarbock R**, Hendig D, Szliska C, Kleesiek K, Götting C. Vascular endothelial growth factor gene polymorphisms as prognostic markers for ocular manifestations in pseudoxanthoma elasticum. *Hum Mol Genet* 2009; **18**: 3344-3351 [PMID: 19483196 DOI: 10.1093/hmg/ddp259]

27 **Szabó Z**, Váradi A, Li Q, Uitto J. ABCC6 does not transport adenosine - relevance to pathomechanism of pseudoxanthoma elasticum. *Mol Genet Metab* 2011; **104**: 421; author reply 422 [PMID: 21813308 DOI: 10.1016/j.ymgme.2011.07.013]

28 **Le Saux O**, Urban Z, Tschuch C, Csiszar K, Bacchelli B, Quaglino D, Pasquali-Ronchetti I, Pope FM, Richards A, Terry S, Bercovitch L, de Paepe A, Boyd CD. Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. *Nat Genet* 2000; **25**: 223-227 [PMID: 10835642 DOI: 10.1038/76102]

29 **Lefthériotis G**, Omarjee L, Le Saux O, Henrion D, Abraham P, Prunier F, Willoteaux S, Martin L. The vascular phenotype in Pseudoxanthoma elasticum and related disorders: contribution of a genetic disease to the understanding of vascular calcification. *Front Genet* 2013; **4**: 4 [PMID: 23408347 DOI: 10.3389/fgene.2013.00004]

30 **Li Q**, Jiang Q, Pfendner E, Váradi A, Uitto J. Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms. *Exp Dermatol* 2009; **18**: 1-11 [PMID: 19054062 DOI: 10.1111/j.1600-0625.2008.00795.x]

31 **Marchione R**, Kim N, Kirsner RS. Pseudoxanthoma elasticum: new insights. *J Invest Dermatol* 2009; **129**: 258 [PMID: 19148211 DOI: 10.1038/jid.2008.407]

32 **Ziegler SG,** Ferreira CR, Pinkerton, AB, Millan JL, Gahl WA, Dietz HC. Novel insights regarding the pathogenesis and treatment of pseudoxanthoma elasticum. 2014. Available from: URL: http://www.ashg.org/2014meeting/abstracts/fulltext/f140120885.htm

33 **Hosen MJ**, Lamoen A, De Paepe A, Vanakker OM. Histopathology of pseudoxanthoma elasticum and related disorders: histological hallmarks and diagnostic clues. *Scientifica* (Cairo) 2012; **2012**: 598262 [PMID: 24278718 DOI: 10.6064/2012/598262]

34 **Hosen MJ**, Coucke PJ, Le Saux O, De Paepe A, Vanakker OM. Perturbation of specific pro-mineralizing signalling pathways in human and murine pseudoxanthoma elasticum. *Orphanet J Rare Dis* 2014; **9**: 66 [PMID: 24775865 DOI: 10.1186/1750-1172-9-66]

35 **Sowa AK**, Kaiser FJ, Eckhold J, Kessler T, Aherrahrou R, Wrobel S, Kaczmarek PM, Doehring L, Schunkert H, Erdmann J, Aherrahrou Z. Functional interaction of osteogenic transcription factors Runx2 and Vdr in transcriptional regulation of Opn during soft tissue calcification. *Am J Pathol* 2013; **183**: 60-68 [PMID: 23644099 DOI: 10.1016/j.ajpath.2013.03.007]

36 **Kuzaj P**, Kuhn J, Michalek RD, Karoly ED, Faust I, Dabisch-Ruthe M, Knabbe C, Hendig D. Large-scaled metabolic profiling of human dermal fibroblasts derived from pseudoxanthoma elasticum patients and healthy controls. *PLoS One* 2014; **9**: e108336 [PMID: 25265166 DOI: 10.1371/journal.pone.0108336]

37 **Vanakker OM**, Martin L, Schurgers LJ, Quaglino D, Costrop L, Vermeer C, Pasquali-Ronchetti I, Coucke PJ, De Paepe A. Low serum vitamin K in PXE results in defective carboxylation of mineralization inhibitors similar to the GGCX mutations in the PXE-like syndrome. *Lab Invest* 2010; **90**: 895-905 [PMID: 20368697 DOI: 10.1038/labinvest.2010.68]

38 **Miglionico R**, Armentano MF, Carmosino M, Salvia AM, Cuviello F, Bisaccia F, Ostuni A. Dysregulation of gene expression in ABCC6 knockdown HepG2 cells. *Cell Mol Biol Lett* 2014; **19**: 517-526 [PMID: 25169437 DOI: 10.2478/s11658-014-0208-2]

39 **Bacchelli B**, Quaglino D, Gheduzzi D, Taparelli F, Boraldi F, Trolli B, Le Saux O, Boyd CD, Ronchetti IP. Identification of heterozygote carriers in families with a recessive form of pseudoxanthoma elasticum (PXE). *Mod Pathol* 1999; **12**: 1112-1123 [PMID: 10619263]

40 **Johnson K**, Jung A, Murphy A, Andreyev A, Dykens J, Terkeltaub R. Mitochondrial oxidative phosphorylation is a downstream regulator of nitric oxide effects on chondrocyte matrix synthesis and mineralization. *Arthritis Rheum* 2000; **43**: 1560-1570 [PMID: 10902761 DOI: 10.1002/1529-0131(200007)43: 7<1560: : AID-ANR21>3.0.CO; 2-S]

41 **Boraldi F**, Annovi G, Bartolomeo A, Quaglino D. Fibroblasts from patients affected by Pseudoxanthoma elasticum exhibit an altered PPi metabolism and are more responsive to pro-calcifying stimuli. *J Dermatol Sci* 2014; **74**: 72-80 [PMID: 24461675 DOI: 10.1016/j.jdermsci.2013.12.008]

42 **Jansen RS**, Duijst S, Mahakena S, Sommer D, Szeri F, Váradi A, Plomp A, Bergen AA, Oude Elferink RP, Borst P, van de Wetering K. ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. *Arterioscler Thromb Vasc Biol* 2014; **34**: 1985-1989 [PMID: 24969777 DOI: 10.1161/ATVBAHA.114.304017]

43 **Matsuo FS**, Berbert AL, Mantese SA, Loyola AM, Cardoso SV, de Faria PR. Pseudoxanthoma elasticum of the skin with involvement of the oral cavity. *Case Rep Dent* 2013; **2013**: 490785 [PMID: 23762643 DOI: 10.1155/2013/490785]

44 **Lebwohl M**, Neldner K, Pope FM, De Paepe A, Christiano AM, Boyd CD, Uitto J, McKusick VA. Classification of pseudoxanthoma elasticum: report of a consensus conference. *J Am Acad Dermatol* 1994; **30**: 103-107 [PMID: 8277008 DOI: 10.1016/S0190-9622(08)81894-4]

45 **Costrop LM**, Vanakker OO, Van Laer L, Le Saux O, Martin L, Chassaing N, Guerra D, Pasquali-Ronchetti I, Coucke PJ, De Paepe A. Novel deletions causing pseudoxanthoma elasticum underscore the genomic instability of the ABCC6 region. *J Hum Genet* 2010; **55**: 112-117 [PMID: 20075945 DOI: 10.1038/jhg.2009.132]

46 **Li Q**, Grange DK, Armstrong NL, Whelan AJ, Hurley MY, Rishavy MA, Hallgren KW, Berkner KL, Schurgers LJ, Jiang Q, Uitto J. Mutations in the GGCX and ABCC6 genes in a family with pseudoxanthoma elasticum-like phenotypes. *J Invest Dermatol* 2009; **129**: 553-563 [PMID: 18800149 DOI: 10.1038/jid.2008.271]

47 **Vanakker OM**, Martin L, Gheduzzi D, Leroy BP, Loeys BL, Guerci VI, Matthys D, Terry SF, Coucke PJ, Pasquali-Ronchetti I, De Paepe A. Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. *J Invest Dermatol* 2007; **127**: 581-587 [PMID: 17110937 DOI: 10.1038/sj.jid.5700610]

48 **Li Q**, Schurgers LJ, Smith AC, Tsokos M, Uitto J, Cowen EW. Co-existent pseudoxanthoma elasticum and vitamin K-dependent coagulation factor deficiency: compound heterozygosity for mutations in the GGCX gene. *Am J Pathol* 2009; **174**: 534-540 [PMID: 19116367 DOI: 10.2353/ajpath.2009.080865]

49 **Nitschke Y**, Baujat G, Botschen U, Wittkampf T, du Moulin M, Stella J, Le Merrer M, Guest G, Lambot K, Tazarourte-Pinturier MF, Chassaing N, Roche O, Feenstra I, Loechner K, Deshpande C, Garber SJ, Chikarmane R, Steinmann B, Shahinyan T, Martorell L, Davies J, Smith WE, Kahler SG, McCulloch M, Wraige E, Loidi L, Höhne W, Martin L, Hadj-Rabia S, Terkeltaub R, Rutsch F. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. *Am J Hum Genet* 2012; **90**: 25-39 [PMID: 22209248 DOI: 10.1016/j.ajhg.2011.11.020]

50 **Hendig D**, Knabbe C, Götting C. New insights into the pathogenesis of pseudoxanthoma elasticum and related soft tissue calcification disorders by identifying genetic interactions and modifiers. *Front Genet* 2013; **4**: 114 [PMID: 23802012 DOI: 10.3389/fgene.2013.00114]

51 **Hosen MJ**, Van Nieuwerburgh F, Steyaert W, Deforce D, Martin L, Leftheriotis G, De Paepe A, Coucke PJ, Vanakker OM. Efficiency of exome sequencing for the molecular diagnosis of pseudoxanthoma elasticum. *J Invest Dermatol* 2015; **135**: 992-998 [PMID: 25264593 DOI: 10.1038/jid.2014.421]

52 **Vanakker OM**, De Paepe A. Pharmacogenomics in children: advantages and challenges of next generation sequencing applications. *Int J Pediatr* 2013; **2013**: 136524 [PMID: 23401694 DOI: 10.1155/2013/136524]

53 **Ellabban AA**, Hangai M, Yamashiro K, Nakagawa S, Tsujikawa A, Yoshimura N. Tomographic fundus features in pseudoxanthoma elasticum: comparison with neovascular age-related macular degeneration in Japanese patients. *Eye* (Lond) 2012; **26**: 1086-1094 [PMID: 22653517 DOI: 10.1038/eye.2012.101]

54 **Wang AR**, Fonder MA, Telang GH, Bercovitch L, Robinson-Bostom L. Late-onset focal dermal elastosis: an uncommon mimicker of pseudoxanthoma elasticum. *J Cutan Pathol* 2012; **39**: 957-961 [PMID: 22882354 DOI: 10.1111/j.1600-0560.2012.01979.x]

55 **Kang S**, Fisher GJ, Voorhees JJ. Photoaging and topical tretinoin: therapy, pathogenesis, and prevention. *Arch Dermatol* 1997; **133**: 1280-1284 [PMID: 9382567 DOI: 10.1001/archderm.133.10.1280]

56 **Kligman AM**. Early destructive effect of sunlight on human skin. *JAMA* 1969; **210**: 2377-2380 [PMID: 5395389 DOI: 10.1001/jama.1969.03160390039008]

57 **Balus L**, Amantea A, Donati P, Fazio M, Giuliano MC, Bellocci M. Fibroelastolytic papulosis of the neck: a report of 20 cases. *Br J Dermatol* 1997; **137**: 461-466 [PMID: 9349351 DOI: 10.1046/j.1365-2133.1997.18711957.x]

58 **Rath N**, Bhardwaj A, Kar HK, Sharma PK, Bharadwaj M, Bharija SC. Penicillamine induced pseudoxanthoma elasticum with elastosis perforans serpiginosa. *Indian J Dermatol Venereol Leprol* 2005; **71**: 182-185 [PMID: 16394408 DOI: 10.4103/0378-6323.16234]

59 **Ottolenghi S**, Lanyon WG, Williamson R, Weatherall DJ, Clegg JB, Pitcher CS. Human globin gene analysis for a patient with beta-o/delta beta-thalassemia. *Proc Natl Acad Sci U S A* 1975; **72**: 2294-2299 [PMID: 49057 DOI: 10.1073/pnas.72.6.2294]

60 **Aessopos A**, Farmakis D, Loukopoulos D. Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. *Blood* 2002; **99**: 30-35 [PMID: 11756149 DOI: 10.1182/blood.V99.1.30]

61 **Viljoen DL**, Bloch C, Beighton P. Plastic surgery in pseudoxanthoma elasticum: experience in nine patients. *Plast Reconstr Surg* 1990; **85**: 233-238 [PMID: 2300628 DOI: 10.1097/00006534-199002000-00011]

62 **Ng AB**, O'Sullivan ST, Sharpe DT. Plastic surgery and pseudoxanthoma elasticum. *Br J Plast Surg* 1999; **52**: 594-596 [PMID: 10658119 DOI: 10.1054/bjps.1999.3139]

63 **Akali AU**, Sharpe DT. Cervical midline Z-plasty revision surgery for pseudoxanthoma elasticum. *Br J Plast Surg* 2003; **56**: 289-291 [PMID: 12859928 DOI: 10.1016/S0007-1226(03)00123-1]

64 **Salles AG**, Remigio AF, Moraes LB, Varoni AC, Gemperli R, Ferreira MC. Pseudoxanthoma Elasticum Treatment with Fractional CO2 Laser. *Plast Reconstr Surg Glob Open* 2014; **2**: e219 [PMID: 25426402 DOI: 10.1097/GOX.0000000000000173]

65 **Hamza A**, Lohsiriwat V, Rietjens M. Lipofilling in breast cancer surgery. *Gland Surg* 2013; **2**: 7-14 [PMID: 25083450]

66 **Le Corvaisier-Pieto C**, Joly P, Thomine E, Lair G, Lauret P. [Generalized pseudoxanthoma elasticum combined with vitamin K dependent clotting factors deficiency]. *Ann Dermatol Venereol* 1996; **123**: 555-558 [PMID: 9615107]

67 **Macmillan DC**, Vickers HR. Pseudoxanthoma elasticum and a coagulation defect. *Br J Dermatol* 1971; **84**: 182 [PMID: 5548470]

68 **Rongioletti F**, Bertamino R, Rebora A. Generalized pseudoxanthoma elasticum with deficiency of vitamin K-dependent clotting factors. *J Am Acad Dermatol* 1989; **21**: 1150-1152 [PMID: 2808851 DOI: 10.1016/S0190-9622(89)70320-0]

69 **Vanakker OM**, Leroy BP, Schurgers LJ, Vermeer C, Coucke PJ, De Paepe A. Atypical presentation of pseudoxanthoma elasticum with abdominal cutis laxa: evidence for a spectrum of ectopic calcification disorders? *Am J Med Genet A* 2011; **155A**: 2855-2859 [PMID: 21964806 DOI: 10.1002/ajmg.a.34264]

70 **Li Q**, Schumacher W, Jablonski D, Siegel D, Uitto J. Cutaneous features of pseudoxanthoma elasticum in a patient with generalized arterial calcification of infancy due to a homozygous missense mutation in the ENPP1 gene. *Br J Dermatol* 2012; **166**: 1107-1111 [PMID: 22229486 DOI: 10.1111/j.1365-2133.2012.10811.x]

71 **Rutsch F**, Böyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B, Wittkampf T, Weissen-Plenz G, Fischer RJ, Mughal Z, Gregory JW, Davies JH, Loirat C, Strom TM, Schnabel D, Nürnberg P, Terkeltaub R. Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. *Circ Cardiovasc Genet* 2008; **1**: 133-140 [PMID: 20016754 DOI: 10.1161/CIRCGENETICS.108.797704]

72 **Moran JJ**. Idiopathic arterial calcification of infancy: a clinicopathologic study. *Pathol Annu* 1975; **10**: 393-417 [PMID: 1101174]

73 **Le Boulanger G**, Labrèze C, Croué A, Schurgers LJ, Chassaing N, Wittkampf T, Rutsch F, Martin L. An unusual severe vascular case of pseudoxanthoma elasticum presenting as generalized arterial calcification of infancy. *Am J Med Genet A* 2010; **152A**: 118-123 [PMID: 20034067 DOI: 10.1002/ajmg.a.33162]

74 **Lorenz-Depiereux B**, Schnabel D, Tiosano D, Häusler G, Strom TM. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. *Am J Hum Genet* 2010; **86**: 267-272 [PMID: 20137773 DOI: 10.1016/j.ajhg.2010.01.006]

75 **Brachet C**, Mansbach AL, Clerckx A, Deltenre P, Heinrichs C. Hearing loss is part of the clinical picture of ENPP1 loss of function mutation. *Horm Res Paediatr* 2014; **81**: 63-66 [PMID: 24216977 DOI: 10.1159/000354661]

76 **Freychet C**, Gay C, Lavocat MP, Teyssier G, Patural H, Bacchetta J, Cottalorda J, Meunier BB, Linglart A, Baujat G, Stephan JL. [GACI syndrome: a case report with a neonatal beginning]. *Arch Pediatr* 2014; **21**: 632-636 [PMID: 24768072 DOI: 10.1016/j.arcped.2014.03.004]

77 **Chong CR**, Hutchins GM. Idiopathic infantile arterial calcification: the spectrum of clinical presentations. *Pediatr Dev Pathol* 2008; **11**: 405-415 [PMID: 17990935 DOI: 10.2350/07-06-0297.1]

78 **Sholler GF**, Yu JS, Bale PM, Hawker RE, Celermajer JM, Kozlowski K. Generalized arterial calcification of infancy: three case reports, including spontaneous regression with long-term survival. *J Pediatr* 1984; **105**: 257-260 [PMID: 6747757 DOI: 10.1016/S0022-3476(84)80123-7]

79 **Ciana G**, Trappan A, Bembi B, Benettoni A, Maso G, Zennaro F, Ruf N, Schnabel D, Rutsch F. Generalized arterial calcification of infancy: two siblings with prolonged survival. *Eur J Pediatr* 2006; **165**: 258-263 [PMID: 16315058 DOI: 10.1007/s00431-005-0035-6]

80 **Samon LM**, Ash KM, Murdison KA. Aorto-pulmonary calcification: an unusual manifestation of idiopathic calcification of infancy evident antenatally. *Obstet Gynecol* 1995; **85**: 863-865 [PMID: 7724139 DOI: 10.1016/0029-7844(94)00362-H]

81 **Rutsch F**, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nürnberg P. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. *Nat Genet* 2003; **34**: 379-381 [PMID: 12881724 DOI: 10.1038/ng1221]

82 **Ruf N**, Uhlenberg B, Terkeltaub R, Nürnberg P, Rutsch F. The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). *Hum Mutat* 2005; **25**: 98 [PMID: 15605415 DOI: 10.1002/humu.9297]

83 **Witzleben CL**. Idiopathic infantile arterial calcification--a misnomer? *Am J Cardiol* 1970; **26**: 305-309 [PMID: 4196111 DOI: 10.1016/0002-9149(70)90798-8]

84 **Morton R**. Idiopathic arterial calcification in infancy. *Histopathology* 1978; **2**: 423-432 [PMID: 730123 DOI: 10.1111/j.1365-2559.1978.tb01736.x]

85 **Rani H**, Rao R, Rao U, Dinesh U, Ramamurthy B. Idiopathic infantile arterial calcification with thrombotic microangiopathy--a unique case. *Fetal Pediatr Pathol* 2010; **29**: 413-418 [PMID: 21043566 DOI: 10.3109/15513815.2010.505625]

86 **Glatz AC**, Pawel BR, Hsu DT, Weinberg P, Chrisant MR. Idiopathic infantile arterial calcification: two case reports, a review of the literature and a role for cardiac transplantation. *Pediatr Transplant* 2006; **10**: 225-233 [PMID: 16573612 DOI: 10.1111/j.1399-3046.2005.00414.x]

87 **Feigenbaum A**, Müller C, Yale C, Kleinheinz J, Jezewski P, Kehl HG, MacDougall M, Rutsch F, Hennekam RC. Singleton-Merten syndrome: an autosomal dominant disorder with variable expression. *Am J Med Genet A* 2013; **161A**: 360-370 [PMID: 23322711 DOI: 10.1002/ajmg.a.35732]

88 **Bonugli FS**. Involvement of the aortic valve and ascending aorta in congenital syphilis. A review. *Br J Vener Dis* 1961; **37**: 257-267 [PMID: 13871110 DOI: 10.1136/sti.37.4.257]

89 **Heggtveit HA**. Syphilitic Aortitis. A clinicopathologic autopsy study of 100 cases, 1950 to 1960. *Circulation* 1964; **29**: 346-355 [PMID: 14128825 DOI: 10.1161/01.CIR.29.3.346]

90 **Meyer WW**, Lind J. Calcifications of iliac arteries in newborns and infants. *Arch Dis Child* 1972; **47**: 364-372 [PMID: 4113749 DOI: 10.1136/adc.47.253.364]

91 **Ramjan KA**, Roscioli T, Rutsch F, Sillence D, Munns CF. Generalized arterial calcification of infancy: treatment with bisphosphonates. *Nat Clin Pract Endocrinol Metab* 2009; **5**: 167-172 [PMID: 19229237 DOI: 10.1038/ncpendmet1067]

92 **van der Sluis IM**, Boot AM, Vernooij M, Meradji M, Kroon AA. Idiopathic infantile arterial calcification: clinical presentation, therapy and long-term follow-up. *Eur J Pediatr* 2006; **165**: 590-593 [PMID: 16649023 DOI: 10.1007/s00431-006-0146-8]

93 **Meradji M**, de Villeneuve VH, Huber J, de Bruijn WC, Pearse RG. Idiopathic infantile arterial calcification in siblings: radiologic diagnosis and successful treatment. *J Pediatr* 1978; **92**: 401-405 [PMID: 416189 DOI: 10.1016/S0022-3476(78)80427-2]

94 **Otero JE**, Gottesman GS, McAlister WH, Mumm S, Madson KL, Kiffer-Moreira T, Sheen C, Millán JL, Ericson KL, Whyte MP. Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy. *J Bone Miner Res* 2013; **28**: 419-430 [PMID: 22972716 DOI: 10.1002/jbmr.1752]

95 **Marrott PK**, Newcombe KD, Becroft DM, Friedlander DH. Idiopathic infantile arterial calcification with survival to adult life. *Pediatr Cardiol* 1984; **5**: 119-122 [PMID: 6473121 DOI: 10.1007/BF02424963]

96 **Towler DA**. Inorganic pyrophosphate: a paracrine regulator of vascular calcification and smooth muscle phenotype. *Arterioscler Thromb Vasc Biol* 2005; **25**: 651-654 [PMID: 15790939 DOI: 10.1161/01.ATV.0000158943.79580.9d]

97 **Keutel J**, Jörgensen G, Gabriel P. [A new autosomal-recessive hereditary syndrome. Multiple peripheral pulmonary stenosis, brachytelephalangia, inner-ear deafness, ossification or calcification of cartilages]. *Dtsch Med Wochenschr* 1971; **96**: 1676-1681 passim [PMID: 5099199 DOI: 10.1055/s-0028-1110200]

98 **Weaver KN**, El Hallek M, Hopkin RJ, Sund KL, Henrickson M, Del Gaudio D, Yuksel A, Acar GO, Bober MB, Kim J, Boyadjiev SA. Keutel syndrome: report of two novel MGP mutations and discussion of clinical overlap with arylsulfatase E deficiency and relapsing polychondritis. *Am J Med Genet A* 2014; **164A**: 1062-1068 [PMID: 24458983 DOI: 10.1002/ajmg.a.36390]

99 **Khosroshahi HE**, Sahin SC, Akyuz Y, Ede H. Long term follow-up of four patients with Keutel syndrome. *Am J Med Genet A* 2014; **164A**: 2849-2856 [PMID: 25123378 DOI: 10.1002/ajmg.a.36699]

100 **Miller SF**. Brachytelephalangy with sparing of the fifth distal phalanx: a feature highly suggestive of Keutel syndrome. *Pediatr Radiol* 2003; **33**: 186-189 [PMID: 12612818 DOI: 10.1007/s00247-002-0846-9]

101 **Cormode EJ**, Dawson M, Lowry RB. Keutel syndrome: clinical report and literature review. *Am J Med Genet* 1986; **24**: 289-294 [PMID: 3717211 DOI: 10.1002/ajmg.1320240209]

102 **Fryns JP**, van Fleteren A, Mattelaer P, van den Berghe H. Calcification of cartilages, brachytelephalangy and peripheral pulmonary stenosis. Confirmation of the Keutel syndrome. *Eur J Pediatr* 1984; **142**: 201-203 [PMID: 6468443 DOI: 10.1007/BF00442449]

103 **Khosroshahi HE**, Uluoğlu O, Olguntürk R, Başaklar C. Keutel syndrome: a report of four cases. *Eur J Pediatr* 1989; **149**: 188-191 [PMID: 2515061 DOI: 10.1007/BF01958278]

104 **Munroe PB**, Olgunturk RO, Fryns JP, Van Maldergem L, Ziereisen F, Yuksel B, Gardiner RM, Chung E. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. *Nat Genet* 1999; **21**: 142-144 [PMID: 9916809 DOI: 10.1038/5102]

105 **Hale JE**, Fraser JD, Price PA. The identification of matrix Gla protein in cartilage. *J Biol Chem* 1988; **263**: 5820-5824 [PMID: 3258600]

106 **Luo G**, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. *Nature* 1997; **386**: 78-81 [PMID: 9052783 DOI: 10.1038/386078a0]

107 **Schurgers LJ**, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, Vermeer C, Weissberg PL, Proudfoot D. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. *J Thromb Haemost* 2007; **5**: 2503-2511 [PMID: 17848178 DOI: 10.1111/j.1538-7836.2007.02758.x]

108 **Cranenburg EC**, VAN Spaendonck-Zwarts KY, Bonafe L, Mittaz Crettol L, Rödiger LA, Dikkers FG, VAN Essen AJ, Superti-Furga A, Alexandrakis E, Vermeer C, Schurgers LJ, Laverman GD. Circulating matrix γ-carboxyglutamate protein (MGP) species are refractory to vitamin K treatment in a new case of Keutel syndrome. *J Thromb Haemost* 2011; **9**: 1225-1235 [PMID: 21435166 DOI: 10.1111/j.1538-7836.2011.04263.x]

109 **Hur DJ**, Raymond GV, Kahler SG, Riegert-Johnson DL, Cohen BA, Boyadjiev SA. A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome. *Am J Med Genet A* 2005; **135**: 36-40 [PMID: 15810001 DOI: 10.1002/ajmg.a.30680]

110 **Hou JW**. Fetal warfarin syndrome. *Chang Gung Med J* 2004; **27**: 691-695 [PMID: 15605910]

111 **Napolitano M**, Mariani G, Lapecorella M. Hereditary combined deficiency of the vitamin K-dependent clotting factors. *Orphanet J Rare Dis* 2010; **5**: 21 [PMID: 20630065 DOI: 10.1186/1750-1172-5-21]

112 **Casarin A**, Rusalen F, Doimo M, Trevisson E, Carraro S, Clementi M, Tenconi R, Baraldi E, Salviati L. X-linked brachytelephalangic chondrodysplasia punctata: a simple trait that is not so simple. *Am J Med Genet A* 2009; **149A**: 2464-2468 [PMID: 19839041 DOI: 10.1002/ajmg.a.33039]

113 **Moskowitz MA**, Winickoff RN, Heinz ER. Familial calcification of the basal ganglions: a metabolic and genetic study. *N Engl J Med* 1971; **285**: 72-77 [PMID: 4326703 DOI: 10.1056/NEJM197107082850202]

114 **Kousseff BG**. Fahr disease: report of a family and a review. *Acta Paediatr Belg* 1980; **33**: 57-61 [PMID: 7405589]

115 **Billard C**, Dulac O, Bouloche J, Echenne B, Lebon P, Motte J, Robain O, Santini JJ. Encephalopathy with calcifications of the basal ganglia in children. A reappraisal of Fahr's syndrome with respect to 14 new cases. *Neuropediatrics* 1989; **20**: 12-19 [PMID: 2654691 DOI: 10.1055/s-2008-1071258]

116 **Saleem S**, Aslam HM, Anwar M, Anwar S, Saleem M, Saleem A, Rehmani MA. Fahr's syndrome: literature review of current evidence. *Orphanet J Rare Dis* 2013; **8**: 156 [PMID: 24098952 DOI: 10.1186/1750-1172-8-156]

117 **Calabrò RS**, Spadaro L, Marra A, Bramanti P. Fahr's disease presenting with dementia at onset: a case report and literature review. *Behav Neurol* 2014; **2014**: 750975 [PMID: 24803731 DOI: 10.1155/2014/750975]

118 **Dildar N**, Akram H, Qasmi IM, Qureshi MN, Khan S. Familial Fahr's disease presenting with Parkinsonism in a young male. *J Coll Physicians Surg Pak* 2014; **24** Suppl 2: S104-S106 [PMID: 24906256]

119 **Wang C**, Li Y, Shi L, Ren J, Patti M, Wang T, de Oliveira JR, Sobrido MJ, Quintáns B, Baquero M, Cui X, Zhang XY, Wang L, Xu H, Wang J, Yao J, Dai X, Liu J, Zhang L, Ma H, Gao Y, Ma X, Feng S, Liu M, Wang QK, Forster IC, Zhang X, Liu JY. Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. *Nat Genet* 2012; **44**: 254-256 [PMID: 22327515 DOI: 10.1038/ng.1077]

120 **Mufaddel AA**, Al-Hassani GA. Familial idiopathic basal ganglia calcification (Fahr`s disease). *Neurosciences* (Riyadh) 2014; **19**: 171-177 [PMID: 24983277]

121 **Hsu SC**, Sears RL, Lemos RR, Quintáns B, Huang A, Spiteri E, Nevarez L, Mamah C, Zatz M, Pierce KD, Fullerton JM, Adair JC, Berner JE, Bower M, Brodaty H, Carmona O, Dobricić V, Fogel BL, García-Estevez D, Goldman J, Goudreau JL, Hopfer S, Janković M, Jaumà S, Jen JC, Kirdlarp S, Klepper J, Kostić V, Lang AE, Linglart A, Maisenbacher MK, Manyam BV, Mazzoni P, Miedzybrodzka Z, Mitarnun W, Mitchell PB, Mueller J, Novaković I, Paucar M, Paulson H, Simpson SA, Svenningsson P, Tuite P, Vitek J, Wetchaphanphesat S, Williams C, Yang M, Schofield PR, de Oliveira JR, Sobrido MJ, Geschwind DH, Coppola G. Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. *Neurogenetics* 2013; **14**: 11-22 [PMID: 23334463 DOI: 10.1007/s10048-012-0349-2]

122 **Westenberger A**, Klein C. The genetics of primary familial brain calcifications. *Curr Neurol Neurosci Rep* 2014; **14**: 490 [PMID: 25212438 DOI: 10.1007/s11910-014-0490-4]

123 **Nicolas G**, Pottier C, Maltête D, Coutant S, Rovelet-Lecrux A, Legallic S, Rousseau S, Vaschalde Y, Guyant-Maréchal L, Augustin J, Martinaud O, Defebvre L, Krystkowiak P, Pariente J, Clanet M, Labauge P, Ayrignac X, Lefaucheur R, Le Ber I, Frébourg T, Hannequin D, Campion D. Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. *Neurology* 2013; **80**: 181-187 [PMID: 23255827 DOI: 10.1212/WNL.0b013e31827ccf34]

124 **Nicolas G**, Pottier C, Charbonnier C, Guyant-Maréchal L, Le Ber I, Pariente J, Labauge P, Ayrignac X, Defebvre L, Maltête D, Martinaud O, Lefaucheur R, Guillin O, Wallon D, Chaumette B, Rondepierre P, Derache N, Fromager G, Schaeffer S, Krystkowiak P, Verny C, Jurici S, Sauvée M, Vérin M, Lebouvier T, Rouaud O, Thauvin-Robinet C, Rousseau S, Rovelet-Lecrux A, Frebourg T, Campion D, Hannequin D. Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. *Brain* 2013; **136**: 3395-3407 [PMID: 24065723 DOI: 10.1093/brain/awt255]

125 **Sanchez-Contreras M**, Baker MC, Finch NA, Nicholson A, Wojtas A, Wszolek ZK, Ross OA, Dickson DW, Rademakers R. Genetic screening and functional characterization of PDGFRB mutations associated with basal ganglia calcification of unknown etiology. *Hum Mutat* 2014; **35**: 964-971 [PMID: 24796542 DOI: 10.1002/humu.22582]

126 **Nicolas G**, Rovelet-Lecrux A, Pottier C, Martinaud O, Wallon D, Vernier L, Landemore G, Chapon F, Prieto-Morin C, Tournier-Lasserve E, Frébourg T, Campion D, Hannequin D. PDGFB partial deletion: a new, rare mechanism causing brain calcification with leukoencephalopathy. *J Mol Neurosci* 2014; **53**: 171-175 [PMID: 24604296 DOI: 10.1007/s12031-014-0265-z]

127 **Nicolas G**, Jacquin A, Thauvin-Robinet C, Rovelet-Lecrux A, Rouaud O, Pottier C, Aubriot-Lorton MH, Rousseau S, Wallon D, Duvillard C, Béjot Y, Frébourg T, Giroud M, Campion D, Hannequin D. A de novo nonsense PDGFB mutation causing idiopathic basal ganglia calcification with laryngeal dystonia. *Eur J Hum Genet* 2014; **22**: 1236-1238 [PMID: 24518837 DOI: 10.1038/ejhg.2014.9]

128 **Keller A**, Westenberger A, Sobrido MJ, García-Murias M, Domingo A, Sears RL, Lemos RR, Ordoñez-Ugalde A, Nicolas G, da Cunha JE, Rushing EJ, Hugelshofer M, Wurnig MC, Kaech A, Reimann R, Lohmann K, Dobričić V, Carracedo A, Petrović I, Miyasaki JM, Abakumova I, Mäe MA, Raschperger E, Zatz M, Zschiedrich K, Klepper J, Spiteri E, Prieto JM, Navas I, Preuss M, Dering C, Janković M, Paucar M, Svenningsson P, Saliminejad K, Khorshid HR, Novaković I, Aguzzi A, Boss A, Le Ber I, Defer G, Hannequin D, Kostić VS, Campion D, Geschwind DH, Coppola G, Betsholtz C, Klein C, Oliveira JR. Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. *Nat Genet* 2013; **45**: 1077-1082 [PMID: 23913003 DOI: 10.1038/ng.2723]

129 **Villa-Bellosta R**, Levi M, Sorribas V. Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-alpha, and Pi. *Pflugers Arch* 2009; **458**: 1151-1161 [PMID: 19506901 DOI: 10.1007/s00424-009-0688-5]

130 **Beall SS**, Patten BM, Mallette L, Jankovic J. Abnormal systemic metabolism of iron, porphyrin, and calcium in Fahr's syndrome. *Ann Neurol* 1989; **26**: 569-575 [PMID: 2817830 DOI: 10.1002/ana.410260412]

131 **Hozumi I,** Kohmura A, Kimura A, Hasegawa T, Honda A, Hayashi Y, Hashimoto K, Yamada M, Sakurai T, Tanaka Y, Satoh M, Inuzuka T. High Levels of Copper, Zinc, Iron and Magnesium, but not Calcium, in the Cerebrospinal Fluid of Patients with Fahr's Disease. *Case Rep Neurol* 2010; **2**: 46-51 [PMID: 20671856 DOI: 10.1159/000313920]

132 **Takagi M**, Ozawa K, Yasuda H, Douke M, Hashimoto K, Hayashi Y, Inuzuka T, Hozumi I. Decreased bioelements content in the hair of patients with Fahr's disease (idiopathic bilateral calcification in the brain). *Biol Trace Elem Res* 2013; **151**: 9-13 [PMID: 23090713 DOI: 10.1007/s12011-012-9529-z]

133 **Kozic D**, Todorovic-Djilas L, Semnic R, Miucin-Vukadinovic I, Lucic M. MR imaging - an unreliable and potentially misleading diagnostic modality in patients with intracerebral calcium depositions. Case report. *Neuro Endocrinol Lett* 2009; **30**: 553-557 [PMID: 20035256]

134 **Livingston JH**, Stivaros S, van der Knaap MS, Crow YJ. Recognizable phenotypes associated with intracranial calcification. *Dev Med Child Neurol* 2013; **55**: 46-57 [PMID: 23121296 DOI: 10.1111/j.1469-8749.2012.04437.x]

135 **Manyam BV**, Bhatt MH, Moore WD, Devleschoward AB, Anderson DR, Calne DB. Bilateral striopallidodentate calcinosis: cerebrospinal fluid, imaging, and electrophysiological studies. *Ann Neurol* 1992; **31**: 379-384 [PMID: 1586138 DOI: 10.1002/ana.410310406]

136 **Avrahami E**, Cohn DF, Feibel M, Tadmor R. MRI demonstration and CT correlation of the brain in patients with idiopathic intracerebral calcification. *J Neurol* 1994; **241**: 381-384 [PMID: 7931433 DOI: 10.1007/BF02033355]

137 **Boller F**, Boller M, Gilbert J. Familial idiopathic cerebral calcifications. *J Neurol Neurosurg Psychiatry* 1977; **40**: 280-285 [PMID: 886353 DOI: 10.1136/jnnp.40.3.280]

138 **Morita M**, Tsuge I, Matsuoka H, Ito Y, Itosu T, Yamamoto M, Morishima T. Calcification in the basal ganglia with chronic active Epstein-Barr virus infection. *Neurology* 1998; **50**: 1485-1488 [PMID: 9596016 DOI: 10.1212/WNL.50.5.1485]

139 **Bonazza S**, La Morgia C, Martinelli P, Capellari S. Strio-pallido-dentate calcinosis: a diagnostic approach in adult patients. *Neurol Sci* 2011; **32**: 537-545 [PMID: 21479613 DOI: 10.1007/s10072-011-0514-7]

140 **Betsholtz C**, Keller A. PDGF, pericytes and the pathogenesis of idiopathic basal ganglia calcification (IBGC). *Brain Pathol* 2014; **24**: 387-395 [PMID: 24946076 DOI: 10.1111/bpa.12158]

141 **Nance MA**, Berry SA. Cockayne syndrome: review of 140 cases. *Am J Med Genet* 1992; **42**: 68-84 [PMID: 1308368 DOI: 10.1002/ajmg.1320420115]

142 **Lanzi G**, Fazzi E, D'Arrigo S. Aicardi-Goutières syndrome: a description of 21 new cases and a comparison with the literature. *Eur J Paediatr Neurol* 2002; **6** Suppl A: A9-A22; discussion A23-A25, A77-A86 [PMID: 12365365]

143 **Levine MA**. An update on the clinical and molecular characteristics of pseudohypoparathyroidism. *Curr Opin Endocrinol Diabetes Obes* 2012; **19**: 443-451 [PMID: 23076042 DOI: 10.1097/MED.0b013e32835a255c]

144 **St Hilaire C**, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, Carlson-Donohoe H, Lederman RJ, Chen MY, Yang D, Siegenthaler MP, Arduino C, Mancini C, Freudenthal B, Stanescu HC, Zdebik AA, Chaganti RK, Nussbaum RL, Kleta R, Gahl WA, Boehm M. NT5E mutations and arterial calcifications. *N Engl J Med* 2011; **364**: 432-442 [PMID: 21288095 DOI: 10.1056/NEJMoa0912923]

145 **Markello TC**, Pak LK, St Hilaire C, Dorward H, Ziegler SG, Chen MY, Chaganti K, Nussbaum RL, Boehm M, Gahl WA. Vascular pathology of medial arterial calcifications in NT5E deficiency: implications for the role of adenosine in pseudoxanthoma elasticum. *Mol Genet Metab* 2011; **103**: 44-50 [PMID: 21371928 DOI: 10.1016/j.ymgme.2011.01.018]

146 **Yegutkin GG**. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. *Biochim Biophys Acta* 2008; **1783**: 673-694 [PMID: 18302942 DOI: 10.1016/j.bbamcr.2008.01.024]

147 **Aliagas E**, Vidal A, Texidó L, Ponce J, Condom E, Martín-Satué M. High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors. *Mediators Inflamm* 2014; **2014**: 509027 [PMID: 24707115 DOI: 10.1155/2014/509027]

148 **Yang D**, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. *J Clin Invest* 2006; **116**: 1913-1923 [PMID: 16823489 DOI: 10.1172/JCI27933]

149 **Fathi I**, Sakr M. Review of tumoral calcinosis: A rare clinico-pathological entity. *World J Clin Cases* 2014; **2**: 409-414 [PMID: 25232542 DOI: 10.12998/wjcc.v2.i9.409]

150 **Slavin RE**, Wen J, Kumar D, Evans EB. Familial tumoral calcinosis. A clinical, histopathologic, and ultrastructural study with an analysis of its calcifying process and pathogenesis. *Am J Surg Pathol* 1993; **17**: 788-802 [PMID: 8338191 DOI: 10.1097/00000478-199308000-00004]

151 **Topaz O**, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. *Nat Genet* 2004; **36**: 579-581 [PMID: 15133511 DOI: 10.1038/ng1358]

152 **Jose J**, Fitcher B, Clifford PD. Familial tumoral calcinosis. *Am J Orthop* (Belle Mead NJ) 2010; **39**: E111-E113 [PMID: 21290017]

153 **Ichikawa S**, Baujat G, Seyahi A, Garoufali AG, Imel EA, Padgett LR, Austin AM, Sorenson AH, Pejin Z, Topouchian V, Quartier P, Cormier-Daire V, Dechaux M, Malandrinou FCh, Singhellakis PN, Le Merrer M, Econs MJ. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. *Am J Med Genet A* 2010; **152A**: 896-903 [PMID: 20358599 DOI: 10.1002/ajmg.a.33337]

154 **Kato K**, Jeanneau C, Tarp MA, Benet-Pagès A, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Clausen H. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. *J Biol Chem* 2006; **281**: 18370-18377 [PMID: 16638743 DOI: 10.1074/jbc.M602469200]

155 **Urakawa I**, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. *Nature* 2006; **444**: 770-774 [PMID: 17086194 DOI: 10.1038/nature05315]

156 **Nitta K**, Nagano N, Tsuchiya K. Fibroblast growth factor 23/klotho axis in chronic kidney disease. *Nephron Clin Pract* 2014; **128**: 1-10 [PMID: 25402964 DOI: 10.1159/000365787]

157 **Hu MC**, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, Razzaque MS, Rosenblatt KP, Baum MG, Kuro-o M, Moe OW. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. *FASEB J* 2010; **24**: 3438-3450 [PMID: 20466874 DOI: 10.1096/fj.10-154765]

158 **Olsen KM**, Chew FS. Tumoral calcinosis: pearls, polemics, and alternative possibilities. *Radiographics* 2006; **26**: 871-885 [PMID: 16702460 DOI: 10.1148/rg.263055099]

159 **Jalil R**, Roach J, Smith A, Mukundan C. Calcific myonecrosis: a case report and review of the literature. *BMJ Case Rep* 2012; **2012**: pii: bcr2012007186 [PMID: 23060384 DOI: 10.1136/bcr-2012-007186]

160 **Polukhin E**, Durvasula J. Tophaceous gout - even today. *Front Immunol* 2013; **4**: 284 [PMID: 24069020 DOI: 10.3389/fimmu.2013.00284]

161 **Pignolo RJ**, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. *Orphanet J Rare Dis* 2011; **6**: 80 [PMID: 22133093 DOI: 10.1186/1750-1172-6-80]

162 **Moore DD**, Luu HH. Osteosarcoma. *Cancer Treat Res* 2014; **162**: 65-92 [PMID: 25070231 DOI: 10.1007/978-3-319-07323-1\_4]

163 **Ho YY**, Choueka J. Synovial chondromatosis of the upper extremity. *J Hand Surg Am* 2013; **38**: 804-810 [PMID: 23474166 DOI: 10.1016/j.jhsa.2013.01.041]

164 **Bureau NJ**. Calcific tendinopathy of the shoulder. *Semin Musculoskelet Radiol* 2013; **17**: 80-84 [PMID: 23487339 DOI: 10.1055/s-0033-1333941]

165 **Ardolino AM**, Milne BW, Patel PA, Fairhurst J, Clarke NM. Digital calcinosis circumscripta: case series and review of the literature. *J Pediatr Orthop B* 2012; **21**: 443-447 [PMID: 21654339 DOI: 10.1097/BPB.0b013e3283484c15]

166 **Santili C**, Akkari M, Waisberg G, Kessler C, Alcantara Td, Delai PL. Calcinosis universalis: a rare diagnosis. *J Pediatr Orthop B* 2005; **14**: 294-298 [PMID: 15931036 DOI: 10.1097/01202412-200507000-00012]

167 **King JJ**, Brennan KB, Crawford EA, Fox EJ, Ogilvie CM. Surgical complications associated with extensive tumoral calcinosis. *Am J Orthop* (Belle Mead NJ) 2011; **40**: 247-252 [PMID: 21734933]

**P-Reviewer:** Anis S, Shipman A

**S-Editor:** Tian YL **L-Editor: E-Editor:**

Table 1 Causes of metastatic/dystrophic calcification and ectopic ossification

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | **Metastatic calcification** | **Dystrophic calcification** | | **Ectopic ossification** |
| **Primary** | | Primary hyperparathyroidism  Pseudo(pseudo)hypoparathyroidism  HFTC | PXE  PXE-like syndrome  GACI  Keutel syndrome  IBGC  ACDC  AI | | Fibrodysplasia ossificans progressiva |
| **Secondary** | Sarcoidosis  Vitamin D intoxication  Milk-Alkali syndrome  Secondary hyperparathyroidism  Renal failure  Hemodialysis  Tumor lysis  Therapy with vitamin D and phosphate | | | Scleroderma  Dermatomyositis  SLE | Nonhereditary myositis ossificans | |

ACDC: Arterial calcification due to CD73 deficiency; AI: Amelogenesis imperfecta; GACI: Generalized arterial calcification of infancy; HFTC: Hyperphosphatemic familial tumoral calcinosis; IBGC: Idiopathic basal ganglia calcification; PXE: Pseudoxanthoma elasticum; SLE: Systemic lupus erythematosus.

Table 2 Differential diagnosis of pseudoxanthoma elasticum manifestations[1,19,47,49,53-59]

|  |  |
| --- | --- |
| **Disease** | **Distinct differences with PXE** |
| Beta-thalassemia  (PXE phenocopy) | Severe anemia  Reduced production of hemoglobin |
| PXE-like syndrome  (AR; *GGCX* gene) | More severe cutaneous phenotype not restricted to flexural areas  Vitamin K-dependent coagulation factor deficiency |
| GACI  (AR; *ENPP1* gene) | Onset in infancy or early childhood  Arterial stenosis  Early-onset severe myocardial ischemia  High mortality rate in early childhood |
| Fibroelastolytic papulosis, Treatment with D-penicillamine | No ophthalmological or CV phenotype |
| Buschke-Ollendorf syndrome  (AD; *LEMD3* gene) | Skeletal manifestations (osteopoikilosis, stiff joints, osteosclerosis)  No ophthalmological or CV phenotype  No mineralization |
| Solar elastosis | Dermatological features (lentigines, mottled pigmentation, actinic keratoses, telangiectasias, xerotic texture)  No ophthalmological or CV phenotype  No mineralization |
| Late-onset focal dermal elastosis | Onset in 7th to 9th life decade  No ophthalmological or CV phenotype |
| Cutis laxa | No ophthalmological or CV phenotype  Histopathology: scarce and mottled elastic fibers, no mineralization |
| A(R)MD (age-related macular degeneration) | No AS  No CV or dermatological phenotype  Less unique lesions (outer retinal tabulation or Bruch’s membrane undulation) |
| Presumed ocular histoplasmosis | No AS  No CV or dermatological phenotype |

AD: Autosomal dominant; AR: Autosomal recessive; A(R)MD: Age-related macular degeneration; AS: Angioid streaks; CV: Cardiovascular; *ENPP1*: Ectonucleotide pyrophosphatase/phosphodiesterase 1; GACI: Generalized arterial calcification of infancy; *GGCX*: Gamma-glutamyl carboxylase; *LEMD3*: Lem domain-containing protein 3; PXE: Pseudoxanthoma elasticum.

Table 3 Differential diagnosis of the pseudoxanthoma elasticum-like syndrome[19,47]

|  |  |
| --- | --- |
| **Disease** | **Distinct differences with PXE-like syndrome** |
| PXE  (AR; *ABCC6* gene) | More severe CV and ophthalmological manifestations  Skin lesions are less severe and restricted to flexural areas  No coagulation factor deficiency associated  EM: mineralization in the core of the EF |
| Cutis laxa | No retinopathy  No deficiency of coagulation factors  Atherosclerosis and cerebral aneurysm are infrequent  Histopathology: scarce and mottled elastic fibers, no mineralization |

*ABCC6*: Adenosine triphosphate-binding cassette, subfamily C, member 6; AR: Autosomal recessive; CV: Cardiovascular; EF: Elastic fiber; EM: Electron microscopy; PXE: Pseudoxanthoma elasticum.

Table 4 Differential diagnosis of generalized arterial calcification of infancy[73,78,87-90]

|  |  |
| --- | --- |
| Disease | Distinct differences with GACI |
| PXE (AR; *ABCC6*) | GACI-like phenotype possible, however infrequent  CV phenotype usually less severe  No onset in infancy  Dermatological and ophthalmological phenotypes more prominent |
| Singleton-Merten Calcification  (AD; unknown causal gene) | Dental anomalies (delayed eruption and early loss of permanent teeth, alveolar bone erosion)  Osteopenia  Acroosteolysis |
| Metastatic calcification due to hypervitaminosis D, hyperparathyroidism or end-stage renal disease | Different distribution of extravascular calcification (renal tubules, bronchial walls and basal mucosa and muscularis mucosae of the stomach)  Microscopic vascular changes in media instead of intima |
| Congenital syphilis | Only calcification of the (ascending) aorta  Diagnosed mainly in adults  Hutchinson teeth, interstitial keratitis, saber tibiae, saddle-shaped nose  Histopathology: endarteritis obliterans of vasa vasorum with perivascular plasma cells, lymphocytic cuffing and adventitial fibrosis |
| Iliac artery calcification in healthy infants | Only calcification in the common and internal iliac arteries |

*ABCC6*: Adenosine triphosphate-binding cassette, subfamily C, member 6; AD: Autosomal dominant; AR: Autosomal recessive; CV: Cardiovascular; GACI: Generalized arterial calcification of infancy; PXE: Pseudoxanthoma elasticum.

Table 5 Differential diagnosis of Keutel syndrome[98,110-112]

|  |  |
| --- | --- |
| **Disease** | **Distinct differences with Keutel Syndrome** |
| X-linked chondrodysplasia punctata  (XL; *ARSE* gene) | Ichtyosis  Cataracts  Microcephaly, intellectual disability  ASD, VSD, PDA  Failure to thrive in infancy  Age at diagnosis: usually infancy |
| Warfarin embryopathy | Pectus carinatum  Congenital heart defects different from those seen in Keutel syndrome (ASD, PDA, ventriculomegaly) |
| Combined Vitamin K-dependent coagulation factor deficiency | Easy bruising, mucocutaneous bleeding  Osteoporosis with normal serum markers |
| Relapsing Polychondritis | Age at diagnosis: 40-60 yr  Cartilage inflammation, possibly progressing to destruction  Aortic or mitral valvular disease  Facies: saddle nose deformity, multifocal, tender chondritis, including variably floppy or calcified auricles  Cranial neuropathies, hemiplegia |

*ARSE*: Arylsulfatase E; ASD: Atrial septal defect; PDA: Patent ductus arteriosus; VSD: Ventricular septal defect; XL: X-linked.

Table 6 Differential diagnosis of idiopathic basal ganglia calcification[116,140-143]


|  |  |
| --- | --- |
| **Disease** | **Distinct differences with IBGC** |
| Basal ganglia calcification as incidental finding on CT scans/Aging | In 1% of CT scans  Usually benign  No clear etiology, especially when in older patients  Asymptomatic |
| Hypoparathyroidism | Early onset: childhood/adolescence  Hypoparathyroidism, hypocalcemia, hyperphosphatemia  Alopecia, dry hair  Dental dysplasia, caries  Moniliasis  Albright osteodystrophy symptoms (short stature, round facies, obesity, short metacarpals/metatarsals) |
| Pseudohypoparathyroidism  (AD/maternal imprinting; *GNAS*, *GNASAS1* and *STX1A* gene) | Early onset: childhood/adolescence  Hyperparathyroidism, hypocalcemia, hyperphosphatemia  Baseline cAMP in urine low; after Ellsworth Howard test subnormal  Intellectual disability  Albright osteodystrophy symptoms |
| Pseudo-pseudohypoparathyroidism  (AD/paternal imprinting; *GNAS* gene) | Similar phenotype as pseudohypoparathyroidism  Normal serum PTH, calcium and phosphorus  Intellectual disability (more obvious than in PHP) |
| Kenny-Caffey syndrome, type 1  (AR; *TBCE* gene) | Growth delay  Cortical thickening of long bones  Hypocalcemia, hypoparathyroidism |
| PKAN  (AR; *PANK2* gene) | Early onset (10% > 10 yr)  Pigmentary retinopathy |
| DRPLA  (AD; CAG expansion in *DRPLA* gene) | Phenotype similar to IBGC |
| Neuroferritinopathy  (AD; *FTL* gene) | Dysphagia |
| PLOSL  (AR; *TYROBP* and *TREM2* gene) | Radiography: polycystic osseous lesions  Frontal lobe syndrome |
| Cockayne syndrome; Aicardi-Goutières syndrome | Onset in infancy/early childhood |

AD: Autosomal dominant; AR: Autosomal recessive; CAG: Cytosine, adenine, guanine; cAMP: 3’-5’-cyclic adenosine monophosphate; CT: Computed tomography; DRPLA: Dentatorubropallidoluysian atrophy; *FTL*: Ferritin light chain; *GNAS*: GNAS complex locus; *GNASAS1*: GNAS complex locus, antisense transcript 1; IBGC: Idiopathic basal ganglia calcification; *PANK2*: Pantothenate kinase 2; PHP: Pseudohypoparathyroidism; PKAN: Panthothenate kinase-associated neurodegeneration; PLOSL: Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy); PTH: Parathyroid hormone; *STX1A*: syntaxin 1A; *TBCE*: Tubulin-specific chaperone E; *TREM2*: Triggering receptor expressed on myoloid cells 2; *TYROBP*: Tyro protein tyrosine kinase-binding protein.


Table 7 Differential diagnosis of hyperphosphatemic familial tumoral calcinosis[149,151,158-166]

|  |  |
| --- | --- |
| **Disease** | **Distinct differences with HFTC** |
| Calcinosis universalis | Calcium depositions in tendons and muscle tissues  Normophosphatemia  High hemosedimentation  Microcytic and hypochromic anemia |
| Calcinosis circumscripta | Adult onset  Local calcinosis  Fingers symmetrically affected |
| Calcific tendinitis | Adult onset  Calcification limited to tendons |
| Synovial chondromatosis | Lesions arising from synovial tissue  Widespread throughout the body  Not all lesions are calcified |
| Osteosarcoma | Long bone malignant tumor  2nd life decade or late adulthood  No subcutaneous/skin lesions |
| Fibrodysplasia ossificans progressiva  (AD; *ACVR1* gene) | Hallux valgus, monophalangism and/or malformed first metatarsal  Sporadic episodes of painful soft tissue swellings (flare-ups) in 1st life decade |
| Tophaceous gout | Severe form of gout  Severe joint deformity, chronic pain and functional decline  More prominent in Asian population (slow metabolizers) and in young men with strong genetic predisposition |
| Calcific myonecrosis | Post-traumatic (time interval of several years possible)  Lower limbs only |
| NFTC  (AR; *SAMD9* gene) | Reddish-to-hyperpigmented skin lesions during the first year of life (preceding calcified nodules)  Severe conjunctivitis and gingivitis  Normophosphatemia |
| Secondary tumoral calcinosis | Renal insufficiency, hyperparathyroidism, or  hypervitaminosis D |
| Rheumatological diseases | Usually normophosphatemia and – calcemia  Possibly positive results in antinuclear, anti-Smith, anti-centromere and anti-scleroderma antibodies, which should all be negative |

*ACVR1*: Activin A receptor, type 1; AD: Autosomal dominant; AR: autosomal recessive; HFTC: Hyperphosphatemic familial tumoral calcinosis; NFTC: Normophosphatemic familial tumoral calcinosis; *SAMD9*: Sterile alpha motif domain-containing protein 9.



**Figure 1 Schematic representation of the pathophysiological mechanisms leading to ectopic mineralization.** Hepatocyte: Impairment of ABCC6 function leads to upregulation of pro-osteogenic pathways (MSX2-WNT, TGFβ-Smad 2/3, BMP2-Smad-RUNX2), upregulation of their downstream targets and eventually to ectopic mineralization. GGCX carboxylates and hence activates multiple targets, such as coagulation factors and MGP, the latter being a potent BMP2-inhibitor and hence mineralization inhibitor. When GGCX function is impaired, these targets stay inactive, leading to increased mineralization. ENPP1 converts ATP to AMP and PPi, the latter being a mineralization inhibitor. Impairment of this conversion and hence a decrease in the PPi level leads to increase in ectopic mineralization. Peripheral cell: After glycosylation by GALNT3, FGF23 forms a complex with FGFR1 and KL (coreceptor) which leads to increased renal excretion of Pi, a pro-mineralizing agent and decreased 1,25 dihydroxyvitamin D3, causing a decrease in intestinal Pi absorption. NT5E converts AMP to Pi and adenosine, which inhibits the pro-mineralizing TNAP. Impairment of NT5E function leads to increased TNAP activity and decreased PPi concentration, hence leading to ectopic mineralization. Pi is internalized into the peripheral cell by PiT2 and leaves the cell through apoptotic bodies, which cause ectopic mineralization through apoptotic pathways (not shown). In MVs an influx occurs of Pi via PiT2 and of Ca2+, which is facilitated by A and PS. This leads to an accumulation of growing hydroxyapatite crystals, eventually causing the MVs to burst and the crystals to grow in the extracellular matrix. A: Annexin A5; ABCC6: Adenosine triphosphate-binding cassette, subfamily C, member 6; ADP: Adenosine diphosphate; AMP: Adenosine monophosphate; ATP: Adenosine triphosphate; BMP2: Bone morphogenetic protein 2; C: Carboxyl; Ca2+: Calcium 2+; ENPP1: Ectonucleotide pyrophosphatase/phosphodiesterase 1; FGF23: Fibroblast growth factor 23; FGFR1: Fibroblast growth factor receptor 1; G: Glycosyl-; GALNT3: UDP-N-acetyl-alpha-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase 3; GGCX: Gamma-glutamyl carboxylase; HA: Hydroxyapatite; KL: Klotho; MGP: Matrix gla protein; MMP9: Matrix metalloproteinase; MSX2: Muscle segment homeobox, drosophila, homolog of, 2; MV: Matrix vesicle; NT5E: Ecto-5-prime nucleotidase or CD73; OC: Osteocalcine; Pi: Inorganic phosphate; SLC20A2: Solute carrier family 20 (phosphate transporter), member 2; PPi: Inorganic pyrophosphate; PS: Phosphatidyl serine; RUNX2: Runt-related transcription factor; Smad: Mothers against decapentaplegic, drosophila, homolog of; TGFβ: Transforming growth factor β; TNAP: Tissue-non-specific alkaline phosphatase; VEGF: Vascular endothelial growth factor; WNT: Wingless-type MMTV integration site family; II, VII, IX, X: Vitamin K-dependent coagulation factors; 1,25 (OH)2 Vit D3: 1,25-dihydroxyvitamine D3 (calcitriol).



**Figure 2 Dermatological (A-F) and ophthalmological (G-I) manifestations of pseudoxanthoma elasticum.** A-B: Flexural areas can show papular lesions (°) and coalesced plaques of papules (\*); C: Cutaneous peau d’orange; D-E: Additional skin folds; F: Yellowish, reticular pattern on the mucosae of the lip (arrowed); G: Ocular fundi show peau d’orange (circle) and angioid streaks (arrowed); H: Comets and comet tails (arrowed); I: Choroidal and subretinal hemorrhage.



**Figure 3 Cutaneous features of a pseudoxanthoma elasticum-like patient with increased amount of generalized thick leathery skin folds.**



**Figure 4 Transverse computed tomography of the brain displaying symmetrical bilateral ganglia calcification in an idiopathic basal ganglia calcification patient.**